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Abstract
Studies have demonstrated a correlation between stress and an increased risk of
breast cancer. Neuropeptide Y (NPY) is up- regulated in chronic stress and induces
proliferation and chemotaxis of 4T1 breast cancer cells via Y5 receptor (Y5R) activation. In
the studies performed in this thesis, we characterize NPY-Y5R as a regulatory system that
promotes breast cancer metastasis. We compared three cancer cell sublines derived from the
same murine mammary fat pad tumour, that greatly differ in metastatic potential (67NR,
168FARN, and 4T1) in addition to a 4T1-Y5R knockdown established in our labs. In this
thesis we demonstrate significance of up-regulation and cytoplasmic localization of Y5R to
support an aggressively metastasizing breast cancer cell line. Using cellular MRI we
characterized the knockdown of Y5R to alter breast carcinogenesis and metastasis. In this
respect, NPY and its Y5 receptor could be therapeutic targets to combat breast cancer
metastasis.
Keywords: Neuropeptide Y; Y5 receptor; stress; breast cancer; metastasis; 4T1-derived cell
lines; cellular MRI; mouse model
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Chapter 1- Background
1.1 Breast cancer and metastasis
Breast cancer is the second most common form of cancer death in females.1 The 98.8% 5-year
survival rate of localized breast cancer drops to 26.3% when the breast cancer is metastastic at
diagnosis.2 Breast cancer commonly metastasizes to the lung, liver, bone, and brain.3
Cancer metastasis is the dissemination of cells from the primary tumour via the lymphatics or
hematogenously and proliferation at a distant site. Metastasis is an inefficient process supported
by a high number of circulating cancer cells that do not result in the formation of a tumour.4 This
inefficiency is due to the conditions in the metastatic cascade that the cell must withstand prior to
arresting in an alternate site. Cells must successfully intravasate from the primary site into the
vasculature, withstand shear forces in the circulation, extravasate into an alternate site and
successfully form micrometastases in this new microenvironment.5 The primary characteristics
that determine successful metastasis of a cancer cell fate require further investigation.

1.2 Stress and breast cancer
In a study of 1,601 breast cancer patients, 180 (11.2%) had triple negative breast cancer. Patients
with triple negative breast cancer had an increased likelihood of distant recurrence and increased
risk of death within 5 years of diagnosis.6 In triple negative breast cancers, negative for the
estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor
2 (HER-2), treatment with classic hormone therapy and HER-2 directed therapy is futile. The
sole current therapy for triple negative breast cancer is cytotoxic chemotherapy. Therefore, a
novel target for therapy to treat triple-negative breast cancer is required.
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Studies have demonstrated a correlation between elevated stress levels and poor prognosis and
survival in patients with breast cancer.7–11 Independent of body mass index, weight change,
alcohol use, smoking, and physical activity, there is a two-fold increase in breast cancer
recurrence after a single stressful life event, such as a disruption of marriage due to divorce,
separation, or death of a spouse, that do not seem to be mediated or altered by perceptions of
one’s daily stress, adverse personality, or pessimistic attitude.12 In a retrospective study of 94
women with breast cancer recurrence or metastasis, planned comparisons revealed a significantly
longer disease-free interval amongst women who had reported no traumatic or stressful life
events compared to those who had experienced one or more, such as abandonment or close
member of kin dying.13

1.3 Stress-induced release of Neuropeptide Y
Neuropeptide Y (NPY) is most widely expressed in the central and peripheral nervous systems
and plays a major role in cognitive function, feeding patterns, and cardiovascular regulation.14
NPY elicits its ubiquitous effects by binding to G- Protein Coupled Receptors, Y1R, Y2R, Y4R,
Y5R, and Y6R, which have been cloned in mammals.15 NPY is a sympathetic neurotransmitter
that is released in greater quantities during chronic stress and in response to a life-threatening
stressor from sympathetic nerves, adrenal medulla and platelets.16,17 Cold exposure significantly
stimulates the release of NPY in both humans and rodents.18,19 Additionally, exposure of to an
aggressor mouse stimulates the release of NPY in rodents.17 In clinical trials, Y5R antagonist,
MK-0577, proved insufficient as a monotherapy to treat obesity but displayed favourable clinical
safety.20
The pleiotropic influence of NPY varies between males and females. Basal sympathetic nerve
activity is lower in females compared to males.21 Jackson et al. demonstrated that estrogen has
2

the capacity to blunt Y1R activation in skeletal muscle.22 Local noradrenergic mechanisms are
NPY-Y1R mediated and can be modulated by reproductive hormone activity. When estrogen and
progesterone are elevated during the luteal phase, persistent vasoconstriction, is observed.
Furthermore, when estrogen and progesterone are low during the follicular phase
vasoconstriction is abolished. This mechanism is NPY mediated, validated by consistent
vasomotor activity with α and β receptor blockade23 Additionally, Glenn et al. demonstrated that
peptidases, that enhance Y2R and Y5R binding, may be more active in females compared to
males.24
NPY vasoactive effects are not limited to periods of chronic and intense stress. NPY contributes
to maintaining baseline vasomotor tone and sympathetically induced vasoconstriction, supported
by high circulating levels of NPY in patients with hypertension.25 Additionally, the ratio of
released NPY and norepinephrine (NE) from sympathetic nerves is consistent, independent of
the degree of sympathetic stimulation, both contributing to basal vasomotor tone.26

1.4 Neuropeptide Y Receptors Trafficking and Localization
Neuropeptide Y1R-Y6R are Gi-protein coupled receptors with seven transmembrane loops with
the capacity to induce a multitude of downstream cascading effects upon NPY binding. Postactivation, NPY receptors adopt a conformation causing the alpha subunit to convert guanosine
diphosphoate (GDP) to guanosine triphosphate (GTP). As a result Neuropeptide Y receptors
regulate transcription primarily via phosphoinositide 3 (PI3) kinase activity.27 Downstream
effector extracellular signal-regulated kinases (ERK) activity and mitogen-activated protein
kinases (MAPK) are induced and cyclic adenosine monophosphate (cAMP)-dependent pathways
are inhibited, dually contributing to transcriptional regulation. Independent of PI3 kinase activity,
insulin growth factor receptor transactivation by NPY receptors is required to activate ERK.27
3

Figure 1.4.1. NPY-Y receptor Molecular Mechanism. Neuropeptide Y can activate Y1R- Y6R
via binding to the seven transmembrane Gi-protein coupled receptors. Transcriptional regulation
primarily occurs via PI3K and ERK activation and cAMP inhibition.
The affinity of NPY to receptors is regulated by the proteolytic cleavage of NPY by dipeptidyl
peptidase IV (DPPIV) and aminopeptidase P (APP), the resulting cleaved form of NPY binds
preferentially to Y2R and Y5R compared to Y1R.28 Previous studies have shown that activated
NPY Y1 and Y2 receptors internalize via clathrin-coated pits within the cytoplasm and close to
the nucleus in human embryonic kidney cells29. These receptors return to the plasma membrane
by cytosolic β-arrestins directly or transiently enter the rough endoplasmic reticulum.30. In
contrast to Y1R and Y2R, Y5R internalizes less, slower, and requires greater agonist
stimulation29. Of particular interest, human Y1R and Y5R are transcribed in opposite directions
from a common promoter region on chromosome 4q31-q32.31
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Y5R is expressed in a tissue-specific manner, primarily in the colon, ovaries, spleen, and testes.
It is expressed as two isoforms, short and long, with the short form dominating in expression
quantitatively. Therefore, it is suggested that alternative splicing of the 5’UTR could regulate the
level of transcription of the receptor in a tissue specific –manner.32 Y5R has a very long third
intracellular loop compared to Y1R, Y2R, and Y4R.29 Y5R has two binding sites with the
potential to bind high or low affinity to its ligands, NPY, NPY3-36, PYY, PYY3-36, and PP.
Sheriff et al. postulated that the activation of Y5R in normal physiological conditions occurs by
binding the high affinity site and the activation of Y5R in pathophysiological conditions occurs
by binding the low affinity site.33

1.5 Neuropeptide Y and the Immune System
NPY and the immune system modulate each other’s activity bi-directionally. NPY secretion has
been found to be increased in transgenic mice that over-express tumour necrosis factor (TNFα)
and inhibited in human astrocytes by interleukin (IL)-1β.29,30 NPY plays a prominent role in
immune modulator release, Natural Killer Cell (NK) activity, T helper cell differentiation, B cell
homeostasis, and leukocyte trafficking. NPY can elicit its effects by binding and activating Y1R,
Y4R, or Y5R expressed by neutrophils and Y1R expressed by both T cells and granulocytes.31,32
NPY suppresses NK cell activity in a dose-dependent manner in vitro, as well as in the rat spleen
in vivo.33,34 Additionally, NPY supports a shift to T-Helper 2 (Th2) cells through stimulation of
IL-4 secretion, stimulating the conversion of macrophages to anti-inflammatory M2 cells, which
stimulate tumour growth.35,36 Furthermore, NPY induces increased chemotaxis of monocytes and
preferential mobilization of leukocytes.37,38 Therefore, previous studies have suggested indirect
methods of how stress, molecularly transduced via NPY, can affect cancer progression via
immunosuppression.
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1.6 Neuropeptide Y5R in cancer
Neuropeptide Y5R is expressed in cancer cell lines including breast and brain xenograft
models.39-42 In neuroblastoma, Y5R is up-regulated via brain-derived neurotrophic factor
(BDNF). Of particular interest, BDNF was found to induce internalization of Y5R, contributing
to chemo-resistant properties. Furthermore, chemotherapeutic treatment-induced cellular stress
and increased NPY release resulting in increased Y5R expression. Administration of a Y5R
antagonist sensitized the cells to chemotherapy, permitting tumour cell death.39 In Ewing
sarcoma, hypoxia shifts the inhibitory actions of NPY, mediated via Y1R and Y5R, to
proliferative, migratory, and angiogenic via Y2R and Y5R activation by increasing DPPIV
activity.40

1.6.1 NPY-Y5R system and breast cancer
The lateral and anterior cutaneous branches of the second and sixth intercostal nerves
sympathetically innervate the mammary gland, smooth muscle of the areola, skin, and breast
blood vessels.41 In this respect, the breast microenvironment is susceptible to the alterations in
NPY flux induced by chronic stress. This susceptibility has the potential to have a negative
impact on women with family histories of breast cancer, who have an increased basal release of
sympathetic neurotransmitters in response to daily stressors.42 In breast tumour tissue, the NPY
precursor, pre-pro-NPY, is up-regulated accompanied with a down-regulation of NPY (1-36),
however the DPPIV processed form of NPY (3-36) was not assayed.43 Human breast carcinoma
cell lines MCF-7, T47D, MDA MB-231, MDA MB-468, HS578T, BT-549 express significantly
more Y5R than Y1R and Y2R.33 Immunohistochemical observation has revealed the
predominant expression of Y5R with respect to Y1R and Y2R in 4T1 cells grown in murine
mammary fatpad.44

6

1.6.1.1 Proliferation
The rate of cancer cell proliferation is indicative of breast cancer aggression and has an increased
potential to develop into clinically relevant tumours. NPY has been found to be a potent mitogen
in both human breast and murine mammary cancer cells.33,44 The Jackson lab previously
evaluated the independent contributions of Y1R, Y2R, and Y5R on NPY-induced proliferation.
Solely, Y5R-antagonism has the capacity to inhibit the NPY-induced proliferation of 4T1 cancer
cells.44 Sheriff et al. demonstrated the significant proliferative effects of NPY on BT-549 cells,
which is inhibited by Y5R antagonism.33

1.6.1.2 Migration
The capacity of malignant cancer cells to migrate to neighbouring tissue and vasculature is a prerequisite for metastasis. Sheriff et al. demonstrated that the triple negative human MDA-MB-231
cells have an increased propensity to migrate due to Y5R-mediated NPY stimulation.33 Medeiros
et al. demonstrated that NPY-induced chemotaxis of 4T1 cells is primarily via Y2R and Y5R
stimulation in a concentration-dependent manner. This is supported by Y1R antagonism eliciting
no effect on NPY-induced chemotaxis of 4T1 cells, in contrast to migratory inhibition via Y5R
antagonism.44

1.6.1.3 Angiogenesis
Neuropeptide Y stimulates the expression of vascular endothelial growth factor (VEGF), one of
the primary regulatory pro-angiogenic factors in the tumour microenvironment. At physiological
concentrations of NPY-conditioned media from 4T1 and MDA-MB-231 human breast cancer
cells, there was a significant increase in VEGF expression with the capacity to induce
angiogenesis in vitro evaluated by an endothelial tube formation assay. Angiogenesis was
specifically induced by Y5R agonist treatment, in contrast to Y1R and Y2R activation. This
7

experiment elucidated the paracrine mechanism of NPY to activate Y5R inducing the release of
pro-angiogenic VEGF.45

1.6.1.4 Tumourigenicity and Metastasis
Neuropeptide Y is robustly expressed in MFP tumours supplied by sympathetic innervation. The
Jackson lab has chemically-induced sympathectomy, via 6-hydroxydopamine (6-OHDA)
treatment, and found a reduction in mammary fatpad tumour burden by up to 50%.44
Furthermore, oral administration of 90mg/kg of a specific Y5R antagonist TAC557, significantly
attenuated tumour growth and reduced metastatic lung lesion burden.46
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1.7 4T1-derived Cell Lines
In addition to the study of cancer in vitro, cancer cell behaviour should be examined within a
well-recapitulated tumour microenvironment. The 4T1-derived murine mammary carcinoma cell
lines are syngeneic immune competent models and thereby permit this evaluation as opposed to
human cell xenograft models in immune-compromised mice. Identification of specific
biomarkers indicative of metastatic ability would be ideal to determine the fate and risk potential
of cancer cells. The 67NR, 168 FARN, and 4T1 cell lines originate from the same murine
mammary fat pad tumour but differ in metastatic potential.47 The 67NR line was established by
re-plating a monolayer of cells followed by subsequent passaging on gelatin substratum,
resulting in a retained elongated spindle morphology over 40 passages.48 The 168FARN line was
established by re-plating the primary cells onto a non-gelatinized dish and were selected for their
fibroblastic morphology that was retained for 20 passages.

48

The 4T1 cell line was formed by

repeated and sequential selection of lung metastases from intravenous injection.49
67NR cells solely proliferate in the mammary fat pad and do not intravasate to the circulation to
metastasize. 168FARN cells have the capacity to disseminate to the lymph node and do not
metastasize to other parts of the body, in this sense intravasation is fulfilled without resulting in
extravasation. 4T1 cells are able to aggressively metastasize from the primary mammary fatpad
to the lungs, liver, bone and brain primarily hematogenously.47
The 4T1 cell line has been evaluated to effectively model the metastatic progression that is
clinically observed, with a more accurate recapitulation of human metastasis compared to
xenograft models.50 Human stage IV breast cancer is classified by the presence of metastases in
distant organs.51 The features of human stage IV breast cancer can include: (1) the presence of
edema and ulcerations of the skin in and around the primary tumor burden (2) the extension of
10

the primary tumor to the chest cavity lining, (3) the presence of metastatic cells in the draining
lymph nodes.51 All these features are observed when 4T1 primary tumours exceed 3mm in
diameter.50
Despite originating from the same tumour, the cell lines vary morphologically in culture. 67NR
cells form a network-like lattice, in contrast to 168FARN and 4T1 cells that possess a
fibroblastic appearance in culture.47 The cells innately differ in proliferation in vitro; 4T1 cells
have a doubling time of 13.6+1.5h, 168FARN cells have a doubling time of 21+3.9h, and 67NR
cells have a doubling time of 22.4+1.8h.48,49 The growth of the latter two under the influence of
NPY-stimulation is yet to be elucidated.
The inherent phenotypic properties of 67NR and 168FARN cells differ in vitro. 67NR cells
possess comparable adherent capability to 168FARN cells, with diminished migratory potential,
but enhanced invasive properties. Despite the enhanced invasive ability of 67NR cells in vitro,
they do not metastasize in vivo.53

1.8 shRNA knockdown
shRNA knockdown is achieved through successful vector transfection, transcription of shRNA,
and subsequent sequestration and degradation of the target mRNA.54 Vector transfection permits
exploitation of the cellular transcription machinery to transcribe the shRNA. Knockdown can
also be achieved via exogenously introduced and processed siRNA. shRNA is more efficient as
it integrates into the endogenous miRNA pathway and has enhanced loading onto the RNAinduced silencing complex (RISC).55 shRNA results in a knockdown of the targeted mRNA
expression as opposed to a knockout, which alters the genomic sequence.56 Knockout of genomic

11

DNA has the potential to cause detrimental cellular defects due to off-target sequence
deletions.57
Down-regulation of key proteins and receptors can elucidate their contribution to carcinogenesis
and metastasis. shRNA has been employed to degrade HER2/neu protein levels, resulting in
suppression of migration and invasion of breast cancer cells in vitro without alteration of cell
viability.58 shRNA has also been used to reduce the expression of epidermal growth factor
receptor (EGFR) in human breast adenocarcinoma MDA-MB-231 cells by 60% and inhibit
mammary fat pad tumour growth and VEGF secretion in vivo.59 Furthermore, shRNA can be
used to reveal cellular mechanisms in response to therapy. shRNA against metastasis associated1 (MTA-1) recovered the expression of estrogen receptor (ER) alpha, permitting sensitization of
MDA-MB-231 cells to estrogen therapy.60
In this thesis, we investigate the role of Y5R in aggressively metastasizing 4T1 cells by knocking
down Y5R expression facilitated by shRNA. Using this knockdown, we evaluate the contribution
of Y5R to breast cancer cell proliferation and metastasis.

1.9 MRI for evaluating tumour development and metastasis
Magnetic Resonance Imaging (MRI) relies on the properties of hydrogen atoms (protons) to
generate an image. A strong magnetic field causes proton alignment within a subject. A
radiofrequency (RF) transmitter is subsequently turned on then off, causing the protons to be
energized then relaxed, respectively. Energy is emitted from protons when they relax to their
state of equilibrium. The emitted energy produces a signal that is detected and translated by
advanced computer processing. Image contrast exploits the variable relaxation rates of protons in
biological tissue. T1-, T2-and T2*-weighted images are common image contrasts.
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MRI has been widely used to study preclinical mouse models of cancer.61–66 Cancer tissue has
different relaxation rates in contrast with normal tissue, permitting MRI to play a significant role
in the detection, staging and characterization of cancer.67 Tumors may appear as either hypo-or
hyper-intense regions relative to normal tissue, depending on the composition and pulse
sequence used. MRI provides excellent three dimensional anatomic detail and sensitivity to
permit tumour size quantification and location, in addition to edema, hemorrhage, and necrosis.65
In vivo MRI permits non-invasive observation of tumors and metastases longitudinally and in
three dimensions and all spatial orientations. 3D MRI permits in vivo tumour size quantification,
in comparison to histological tissue sections, which must account for shrinkage and deformation
due to the chemical processing, or caliper measurements that assume symmetrical tumour
volume. MRI permits comprehensive analysis of tumour growth rate, tumour development and
metastasis, in contrast to traditional histology.
Contrast agents are employed to enhance regions of interest by shortening both the T1 and T2
times of surrounding tissues, in general affecting one relaxation more than the other.
Paramagnetic contrast agents induce T1 shortening and include gadolinium-(Gd) based and
manganese (Mn) based agents that are detected as bright signals on T1-weighted images.
Superparamagnetic contrast agents all consist of iron-oxide cores and induce T2-shortening
resulting in signal loss or hypointensity.
MRI post-Gd is often used to assess the integrity of the blood-brain-barrier (BBB) and in cancer
imaging the blood-tumour-barrier. Gd is a small-sized contrast agent that is administered
intravenously that provides enhancement of highly perfused tissue and vessel permeability. The
Foster lab has investigated how the BBB permeability is dynamic in accordance with the
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progression of breast cancer metastasis. Gd-enhanced contrast MRI is widely recognized as the
most accurate diagnostic tool in the detection of brain metastases, however the Foster lab found
many metastases detected did not exhibit Gadopentetic acid (Gd-DTPA) enhancement and were
only detectable using bSSFP.64,65 The Foster lab was the first to use 3T MRI and employ bSSFP
to monitor the development of melanoma brain metastases longitudinally. They found bSSFP
imaging permits detection of brain metastases at early time points that can be undetected on T1weighted spin echo (T1wSE) images.64
Post-Gd MRI has also been used to enhance contrast in mouse models of breast cancer. Gd MRI
can be used to identify aggressive tumours, due to high angiogenic activity required to maintain
blood supply to highly proliferative tumour cells. Gd enhancement also permits differentiation
between ER positive luminal breast tumours and triple negative basal breast tumours.69 Gd MRI
has provided insight in the alterations of tumour vasculature with estradiol deprivation in luminal
tumours in a murine orthotopic xenograft model, while basal tumours remain unaffected by
estradiol deprivation.70 Angiogenesis can be indicative of a developed tumour, however the
fluid-filled core of an aggressively metastasizing large tumour can inhibit Gd transport.71

1.10 Iron oxide labeling of cells for MRI
Cellular MRI can be achieved by pre-labeling cells with iron oxide nanoparticles prior to their
administration. Iron oxide contrast agents create negative contrast in T2-or T2*-weighted proton
MR images. The presence of intracellular iron causes a distortion in the local magnetic field
resulting in abnormal signal hypointensity in iron-sensitive images. Therefore, iron-labeled cells
appear as regions of signal loss, or black holes in the MR images. The reduced transverse (T2)
and effective transverse (T2*) relaxation times of nearby nuclei extends to signal loss that
occupies more space than the contrast agent itself resulting in a “blooming artifact.”
14

Iron oxide nanoparticles are classified on the basis of size; ultra small superparamagnetic iron
oxide nanoparticles (USPIO), standard magnetic superparamagnetic iron oxide particles (SPIO),
or micron-size superparamagnetic iron oxide nanoparticles (MPIO). USPIO particles are 1020nm in diameter, SPIO particles are 50-100nm in diameter, and MPIO particles are
approximately 1-5µm in diameter.72
A variety of cell types can be easily loaded with iron oxide nanoparticles by simple coincubation. Nanoparticle uptake is mediated by scavenger receptors, receptor-independent
macropinocytosis, and clathrin–mediated uptake leading to iron oxide storage in endosomes.73
Cancer cells readily uptake MPIOs, for example B16F10 melanoma cells have an uptake
efficiency of 100% with an average iron content of 35pg of Fe/cell.65 Studies show that there is
minimal impact on cell function or phenotype at a wide range of iron loading levels.74,75
Specifically, MPIO or SPIO cancer cell labeling has no discernable effect on viability, in vitro
proliferation, cell apoptosis, necrosis, or in vivo metastasis compared to unlabeled cells.62,65,76
Heyn et al. have demonstrated that even single iron-labeled cells can be detected in vivo. Single
cell detection was permitted due to the aforementioned blooming artifact whereby cancer cells of
approximately 20µm in diameter elicited a signal void of 300µm diameter in the MR image.62

1.11 Cancer Cell Imaging with MRI
Very few groups have used cellular MRI to study cancer cells because the iron label is diluted
over time in proliferative cells, leading to label loss and therefore loss of cell detection. The
Foster lab reported that intracellular iron disappeared after 5 days, when visualized with
photomicrographs, corresponding to the sixth generation of daughter cells.65 Similarly, using
flow cytometry and Perls’ Prussian Blue (PPB) staining, Economopoulos et al. found that less
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than 50% of cells retained detectable quantities of iron four days post-labeling and only 1-2.5%
remained labeled by day 10.61
However, the dilution of iron by cancer cells can be exploited to provide insight in regards to
their proliferative status. The Foster lab has demonstrated that cancer cells that are nonproliferative, or slowly-cycling, will retain the iron label and the fate of these cells can be tracked
with MRI.61 The Foster lab was the first to identify non-proliferative cancer cells in the brain
using iron oxide labeling techniques. Using this effective cell tracking technique, human breast
cancer MDA-MB-231 cells were characterized as proliferative (1.5%), transiently proliferative
(94%), and non-proliferative (4.5%) of the original tumour imaged at day 0.62 Non-proliferative
cells are considered dormant in a state of cell cycle arrest with the potential to form metastases
and are likely the culprit of recurrence.
Magnitzsky et al. exploited iron label retention in slowly proliferative melanoma cells
subcutaneously implanted and found a positive correlation with a biomarker, JARID1B. When
the tumours reached 1cm3 after 5-6 weeks, MR imaging demonstrated that iron-retaining cells
were localized close to the tumour vasculature elucidating the localization of slowly proliferative
cells.63
Townson et al. used cellular MRI to monitor iron-labeled metastatic melanoma cells.80 B16F1
cells were iron-labeled and injected via the mesenteric vein. Mice were treated with either
doxorubicin or vehicle. MRI was used to quantify both the number of liver metastases and
persisting iron-labeled cells. Doxorubicin decreased metastatic growth but did not decrease the
existing metastatic cell populations. This important work showed the ability to assess the effect
of treatment on both proliferative and non-proliferative cell populations and pointed to the lack
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of effect on non-proliferating cells as a factor, which may be responsible for failure rates in
treatment of metastatic disease.77
Economopolous et al. used cellular MRI to monitor the development of iron-labeled primary
MDA-MB-231 mammary fat pad tumours and metastasis to the lymph nodes.64 Over time, the
signal loss associated with the iron-labeled cancer cells was redistributed throughout the tumour
as the cancer cells proliferated. After 4 weeks some iron-labeled MDA-MB-231 cells persisted in
the primary tumour indicating that some of the cells were non-proliferative. Of particular interest
was the observation of iron-labeled MDA-MB-231 cells in lymph nodes. MRI showed signal
loss in axillary or brachial lymph nodes at 3 or 4 weeks post mammary fat pad cell implantation.
The presence of iron-positive MDA-MB-231 cells in nodes was validated by confocal
microscopy; indicating that nonproliferative, or slowly-dividing, cancer cells can leave a primary
tumour and metastasize to the lymph node.61 This paper showed that the proliferative status of
cancer cells can be evaluated by the retention of iron nanoparticles with cellular MRI.
In this thesis we will employ similar techniques to investigate the use of 3D cellular MRI for in
vivo monitoring of the development of 4T1 and 4T1 Y5R-KD primary mammary fat pad tumors,
proliferative status and the incidence of metastases.
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1.12 Objectives, Specific Aim and Hypotheses
The overall objective of this thesis was to elucidate the impact of the NPY-Y5R as a system that
mediates breast cancer development and to develop an in vivo model in which the contributions
of Y5R could be functionally studied.

1.12.1 Specific Aims
1. Evaluate the heterogeneity of expression of Y5R of breast cancer cell lines of various
levels of aggression.
2. Investigate the proliferative potential of the breast cancer cell lines induced by various
concentrations of NPY. Understand the specific role of Y5R in proliferation via receptor
blockade.
3. Establish and validate a 4T1- Y5R knockdown to assess resulting phenotypic alterations
that contribute to breast cancer carcinogenesis.
4. Utilize cellular MRI for the in vivo evaluation of the influence of Y5R on primary tumour
growth, proliferation and metastasis.

1.12.2 Overall Hypothesis
Neuropeptide Y-Y5R is a factor that promotes breast cancer tumourigenicity and metastasis.

1.12.2.1 Specific Hypotheses
1. The metastatic potential coordinates with the Y5R expression of the respective cell lines.
Therefore, metastatic strains of breast cancer with express more Y5R.
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2. NPY stimulates the proliferation of breast cancer cell lines. Y5R antagonism will inhibit
Neuropeptide Y- stimulated proliferation.
3. Knockdown of Y5R will mitigate the proliferative stimulation of NPY.
4. Knockdown of Y5R will reduce the metastatic burden and inhibit proliferation.
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Chapter 2- Neuropeptide Y-Y5R as a Mediating Factor of Breast
Cancer
2.1 Introduction
In Canada, one in nine females is expected develop breast cancer in her life time.1 The
98.8% 5- year survival rate of localized breast cancer drops to 26.3% when the breast cancer has
metastasized.2 Common sites of breast cancer metastasis are the lungs, liver, bone, and brain.3 In
triple negative breast cancers, negative for the estrogen receptor (ER), progesterone receptor
(PR) and human epidermal growth factor receptor 2 (HER-2), treatment with classic hormone
therapy is futile. Therefore, a therapy for a novel target to treat triple-negative breast cancer is
required.
Behavioural and emotional stress has been implicated in breast cancer progression and
metastasis. Studies have demonstrated a correlation between elevated stress levels and poor
prognosis and survival in patients with breast cancer.4–8 Furthermore, there has been documented
support of prolonged survival in breast cancer patients who receive therapeutic emotional
support.6,9,10 Swim stress, surgical stress, social confrontation, and hypothermia in animal stress
models have been shown to promote lung metastasis from injected breast cancer cells.11–14
Neuropeptide Y is a sympathetic neurotransmitter peripherally released from sympathetic
nerves, adrenal medulla and platelets.15 The lateral and anterior cutaneous branches of the second
and sixth intercostal nerves sympathetically innervate the mammary gland, smooth muscle of the
areola, skin, and breast vessels.16 NPY is released in greater quantities during chronic stress and
in response to a life-threatening stressor. In this respect, the breast microenvironment is
susceptible to the alterations in NPY flux induced by stress. This susceptibility has the potential
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to negatively impact women with family histories of breast cancer who have an increased basal
release of sympathetic neurotransmitters in response to daily stressors.17
NPY elicits its effects by binding and activating Gi- protein coupled receptors (GPCR),
Neuropeptide Y1R-Y6R. Neuropeptide Y5R is expressed in cancer cell lines including breast
and brain xenograft models.12-15 The Jackson lab has studied the influence of Neuropeptide Y in
the murine 4T1 breast cancer cell line. The 4T1 cell line aggressively metastasizes to lungs, liver,
bone and brain primarily hematogenously.20 They have shown that NPY supports proliferation,
migration, angiogenesis, and metastasis of 4T1 cells. Furthermore, they have shown that Y5R
activation significantly contributes to these NPY supported cancerous processes.21,22 Although
the contribution of the NPY and Y5R has been well characterized in the 4T1 cell line, the
influence of this system has yet to be characterized in cell lines of various metastatic potentials.
In this thesis, we aim to expand on the previous findings from the Jackson lab to further
elucidate the impact of the NPY-Y5R as a system that mediates breast cancer metastasis and to
develop an in vivo model in which the contributions of Y5R can be functionally studied. To meet
this objective, we have investigated three cell lines with various metastatic capacities and
investigated the role of Y5R and NPY-stimulated proliferation. Furthermore, we investigated the
role of Y5R in aggressively metastasizing 4T1 cells by knocking down Y5R expression
facilitated by shRNA. Using this knockdown, we evaluate the contribution of Y5R to breast
cancer cell proliferation in vitro and metastasis in vivo. To study this in vivo we used cellular
MRI to monitor tumour growth and metastasis and track the fate of iron oxide pre-labeled cancer
cells
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If a direct link can be established between the physiological stress response and breast
cancer progression, NPY and its Y5 receptor could be potential therapeutic targets to combat
breast cancer metastasis.

2.2 Methods
2.2.1 IN VITRO EXPERIMENTS
In vitro experiments were conducted to characterize the expression of Y5R in three cell lines of
various metastatic potential; 67NR, 168 FARN, and 4T1. The proliferation of each cell line was
investigated under the stimulation of NPY and Y5R blockade, to elucidate the specific
contribution of the receptor.

2.2.1.1 Cell Culture
4T1 cells were a gift from Dr. Fred Miller (Wayne State University, Michigan USA),
168FARN and 67NR cells, were a gift from Dr. Ann Chambers (London Health Sciences Centre,
London, Canada). The 67NR, 168 FARN, and 4T1 cell lines originate from the same murine
mammary fat pad tumour with different metastatic potentials.49 67NR cells solely proliferate in
the mammary fat pad and do not intravasate into vessels to metastasize. 168FARN cells have the
capacity to disseminate to the lymph node but do not metastasize to other parts of the body. 4T1
cells are able to aggressively metastasize from the primary mammary fatpad to the lungs, liver,
bone and brain.
Cells were cultivated in high glucose Dulbecco’s Minimal Essential Medium (DMEM)
supplemented with 10% sterile FBS. Cells were incubated at 37oC and 5% carbon dioxide. At
approximately 80% confluency, cells were washed with PBS and passaged using 0.25% trypsinEDTA treatment for dissociation.
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2.2.1.2 Development of a 4T1-Y5R Knockdown Cell Line
A 4T1 Y5R-Knockdown (KD) cell line was established to directly study the role of Y5R
in an aggressively metastasizing breast cancer cell line. 3x105 4T1 cells were plated in a 6 well
plate and grown to 50% confluence. Y5R specific shRNA green fluorescent protein positive
(GFP+) expression plasmids (OriGene NM 006174) were suspended in 50µl of ddH2O to a final
concentration of 100ng/µl. 1µg of shRNA was diluted in 250µl of Opti-MEM I (Gibco 51985).
3µl of LipofectamineTM 3000 (ThermoFisher Scientific, Waltham, MA, USA) was added to
diluted shRNA and incubated for 15 minutes at room temperature. Cells were incubated with the
shRNA mixture at 37oC and 5% CO2 for 72h. These transfection steps toward establishing the
4T1 Y5R-KD cell line were completed by Dr. Phil Medeiros, a previous PhD student in the
Jackson lab.
Cells that had previously been transfected with Y5R specific shRNA GFP+ expression
plasmids were thawed, re-suspended and analyzed for GFP. Cells were re- suspended in 1% FBS
in PBS and were then analyzed for live GFP+ containing cells by fluorescent-activated cell
sorting (FACS). To determine viability, cells were stained with 7-Aminoactinomycin D (7AAD)
viability dye (ThermoFisher Scientific, Waltham, MA, USA) for 10 minutes on ice prior to
sorting. FACS was conducted on a FACSAriaIII system (BD Biosciences, Mississauga, ON,
Canada) using a 100µm filter and parental 4T1 cells were used as a negative control.
One cell was seeded per well in four 96 well- plates using a FACSAriaIII to develop
clonal colonies. Fluorescent colonies were trypsinized and expanded for GFP positive purity
analysis and sorting. Purity greater than 95% prior to sort was deemed as stable transfection.
FACS data was analyzed using BD FACSDiva Shortware version 8.0.1.
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2.2.1.3 Immunocytochemistry
To determine the presence and localization of Y5R, immunocytochemistry was
conducted on 67NR, 168FARN, 4T1 and 4T1 Y5R-KD cells. 105 cells of each strain were grown
on sterile glass coverslips for 48hr, then fixed in ice-cold 4% paraformaldehyde for 15 min. Cells
were washed in ice- cold phosphate-buffered saline (PBS; 2.68mM KCL, 1.46mMKH2PO4,
137mM Nal and 6.48mM Na2HPO4) and permeabilized in 0.25% (v/v) Triton-X 100 (in PBS) for
20 min at room temperature followed by PBS washes. Following 10 min blocking in 1.5%
normal goat serum (in PBS), excess blocking reagent was removed, and replaced with 2ml of
diluted (1:1000) primary antibody specific to NPY Y5R (Cat no. ab133757 Abcam, San
Francisco, CA, USA) for 1hr at room temperature. Cells were washed, incubated in secondary
antibody (biotinylated goat anti-rabbit secondary, 4µg/ml in 0.1% blocking serum in PBS) for 30
minutes at room temperature, washed and incubated in 1:1 avidin:biotin complex (ABC)
(Vectastain Elite ABC® Kit (Standard), Cat. no. PK-6100, Vector Laboratories Inc.,
Burlingame, CA) solution for 30 min. After washing, cells were incubated in 3,3
diaminobenzidine (DAB Peroxidase Substrate Kit, 3,3’-diaminobenzidine, Cat. no. SK-4100,
Vector Laboratories Inc., Burlingame, CA) for 8 minutes, rinsed, cleared and mounted.

2.2.1.4 Western Blot Analysis
To quantify and compare the expression of Y5R between 67NR, 168FARN, 4T1, and
4T1 Y5R-KD cell lines, Western Blot analysis was conducted. Cultured cells from a 75cm2 flask
were washed in ice cold PBS and then lysed in 1.5ml RIPA lysis buffer containing protease
inhibitors (104mM AEBSF, 80 µM aprotinin, 2.1 mM leupeptin, 3.6 mM bestatin, 1.5 mM
pepstatin A, 1.4 mM E-64). Cells were scraped and then lysed using a 27- gauge needle with
syringe. Cells were centrifuged for 10 minutes at 14,000 rpm at 4oC. Supernatant was collected
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and stored at -20oc until protein concentration was determined.
A Bradford assay (Bradford, 1976) was performed to determine total protein
concentration of samples. Fifteen micrograms of protein from each sample were loaded on a 4%
to 12% gradient gel and separated by SDS- PAGE. After electrophoresis, proteins were
transferred at a constant voltage to polyvinylidene fluoride membranes. Membranes were
blocked in 5% Bovine Serum Albumin (BSA) in Tris- Buffered Saline + Tween 20 (0.5%)
(TTBS) for 1 hr. Membranes were then incubated in primary monoclonal antibody specific to
NPY Y5R (Cat no. ab133757 Abcam, San Francisco, CA, USA) in 5% BSA- TTBS at a
concentration of 1:1000 at 4oC overnight. Membranes were washed three times in TTBS then
incubated in secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit IgD,
1:20000) in 2% BSA-TTBS for 1hr. Membranes were washed three times and bands were
detected using an Immun- Star WesternC© chemilluminescent kit (Bio- Rad, Hercules, CA,
USA) and imaged with the ChemiDoc XRS System (Bio-Rad, Hercules, CA, USA). Membranes
were washed, stained for total protein using Coomassie Brilliant Blue and imaged using the
ChemiDoc XRS. Densitometric band quantification was performed with Quantity One 1-D
Analysis Software (Bio-Rad, Hercules, CA, USA). Y5R band intensity was normalized to the
respective average lane signal intensity from Coomassie Brilliant Blue staining.

2.2.1.5 Cell Proliferation
In vitro MTS assays were conducted to investigate the effect of NPY on 67NR, 168
FARN and 4T1 cell line proliferation. One thousand two hundred and fifty viable cells were
seeded per well of 96- well plates for 24 hrs in DMEM supplemented with 10% FBS. After 24hrs
media was replaced with experimental medium (DMEM + 2% FBS) containing 10-11 to 10-6M
NPY (Tocris, Minneapolis, MN, USA) or scrambled 10-6M NPY. The proliferative effect of
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NPY was tested using an MTS (3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H tetrazolium) based assay (CellTiter 96 AQueous One Solution, Madison, WI,
USA). Absorbance of the wells at 490nm was measured after 24hr of NPY treatment. These
experiments were conducted on 67NR, 168FARN and 4T1 cells in triplicate (per concentration)
and repeated three times.
Receptor antagonist experiments were conducted to confirm Y5R- mediated proliferation
induced by NPY. Twenty- four hours after cells were seeded, experimental media containing
NPY (10-6M) and Y5R- specific antagonist, L-152 804 (10-4M), was added and cell proliferation
was measured at 24hrs. Drugs were reconstituted in PBS and all treatments were compared to
control cells that were incubated in media without the addition of drugs.

2.2.1.6 Statistics
Statistical analysis was performed using GraphPad software, data are presented as mean
± SEM. Non-linear regression analysis was performed on proliferation assays. Statistical
differences between cell lines for Western blots and between treatments for proliferation assays
were evaluated by one-way ANOVA, followed by Tukey's HSD test. The level of statistical
probability was set at p < 0.05.

2.2.2 IN VIVO EXPERIMENTS
In vivo experiments were conducted on the aggressively metastasizing 4T1 strain and the
4T1 Y5R-KD strain in order to elucidate the role of Y5R in tumourigenicity and metastasis
longitudinally in a biologically relevant murine model.
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2.2.2.1 Iron- Oxide Cell Labeling for Imaging
To allow cancer cells to be visualized by MRI, 2x106 4T1 or 4T1 Y5R KD cells were
plated in 75cm2 flask in 10ml of high glucose DMEM supplemented with 10% sterile FBS and
were incubated for 24 hours at 37oC and 5% carbon dioxide. Cells were then incubated with the
same media containing 50µg/ml flash red fluorescent micron-sized superparamagnetic iron oxide
particles (MPIO) (Bangs Laboratories Inc., Fishers, IN) for 24h. Cells were washed three times
with 10ml of 37oC HBSS and trypsinized with 0.25% trypsin-EDTA. Cells were centrifuged for
5 minutes at 1000RPM, the supernatant was aspirated and cells were re-suspended in 12 ml of
HBSS three times. Cells were concentrated to 6x106/ml for injection.
To verify cell labeling, 3x105 cells were cytospun onto a slide and fixed in 3:1 methanol:
glacial acetic acid. Cells were stained with 1% potassium hexacyano-ferrate (III) trihydrate in
1% HCl for 30 minutes. Cells were washed in dH2O prior to counterstain with Nuclear fast red.
Cells were washed and dehydrated in increasing concentrations of 75%, 95%, and 100% ethanol
and xylene prior to being mounted.

2.2.2.2 Animal Model
To establish orthotopic tumours, 3 x 105 MPIO labeled 4T1 cells (n=8) or 4T1 Y5R KD
GFP positive cells (n=9) were injected into the inguinal mammary fat pad of female 6-8 week
BALB/c mice (Charles River Laboratory).

2.2.2.3 Magnetic Resonance Imaging
All imaging was performed on 3T MRI scanner (General Electric Medical Scanner,
Milwaukee, WI) using a custom- built gradient coil insert with an inner diameter of 17.5cm,
maximum gradient strength of 500mT/m and a peak slew rate of 3,000T/m/s, and a custom
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solenoidal whole- mouse body radiofrequency (RF) coil 4cm in length and 3cm in diameter.
Mice were anaesthetized with isoflurane (2% in oxygen) and placed prone in the coil, a warm
saline bag was kept near the RF coil to maintain body temperature, and the mice were wrapped
with gauze and tape for consistent positioning to minimize motion artefact due to respiration.
Images were acquired using bSSFP pulse sequence with 200µm isotropic spatial
resolution. The scan parameters for bSSFP were as follows: repetition time (TR) =6.3ms, echo
time (TE)=3.15ms, flip angle=35o, bandwidth= +/- 31.25kHz, matrix=250x250, field of view
(FOV) was 5x2.5cm (30 minutes), 0.2mm slice thickness, 2 signal averages (NEX)=2, RF phase
cycles=8.

2.2.2.4 Image Analysis
Mouse body three dimensional (3D) bSSFP images were assessed for the appearance of
primary tumours and metastases. Images were observed in all three orientations (axial, sagittal
and coronal). Osirix image analysis software was used to make all measurements from images
acquired in the study. To calculate the volume of the mammary fat pad tumour from MRI,
manual segmentation was conducted in each acquired image using the closed polygon tracing
tool and repulsor tool. Each tumour was segmented as a region of interest (ROI) and total tumour
volume was calculated by using the ROI volume calculation tool in the software package.
To calculate the volume of the region of signal hypointensity within the tumours the
mean signal intensity of the hypointense region was measured and a threshold value (mean signal
+ 2 standard deviations) was applied to the whole tumor volume. This value was normalized to
the total tumour volume. All volume data was statistically compared using Graph Pad Prism
analysis software (GraphPad Software, La Jolla, CA).
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Primary tumour colour maps were generated by assigning colours to three signal intensity
values; blue was assigned to voxels with values equal to the mean signal hypointensity +2SD,
yellow was assigned to voxels with values equal to the mean signal hyperintensity +2SD, and
green was assigned to the remainder of the tumour voxels.

2.2.2.5 Histology and Microscopy
All mice injected with 4T1 cells were euthanized at day 28. Two mice injected with 4T1
Y5R-KD cells were euthanized on each of days 14 and 21 and five were euthanized at day 28.
Mice were cardiac perfused with 4% paraformaldehyde. Lungs and tumours were removed and
immersed in 4% paraformaldehyde for 24 hours followed by increasing concentrations of 10%,
20%, and 30% sucrose to cryoprotect tissues. Lungs and tumours were embedded in Optimal
Cutting Temperature medium in a cryomold. Frozen sections were cut with a cryostat (Leica
Microsystems) with a thickness of 10µm. Tumour sections were cut with 1mm separation
between samples, starting from what was discerned as the center of the tumour to yield three
regions of interest. Lung sections were cut through a pair of lungs with 1mm separation between
samples, starting from what was discerned as an edge of the lung to a midpoint, yielding two
regions of interest. Three samples were taken at each region of interest for tumours and lungs to
be stained with Hematoxylin and Eosin (H&E), Perl’s Prussian Blue (PPB) and Nuclear Fast Red
(NFR), and Immunohistochemistry (IHC).

2.2.2.6 Hematoxylin and Eosin staining
Tumour and lung slides were washed in xylene prior to washes in decreasing
concentrations of ethanol, 100%, 95%, and 70%. Tissues were washed with dH2O and stained
with hemaxtoxylin. Tissues were washed with dH2O, acid ethanol, and H2O prior to eosin
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staining. Tissues were washed and dehydrated in increasing concentrations of 75%, 95%, and
100% ethanol and xylene prior to being mounted.

2.2.2.7 Perls’ Prussian Blue and Nuclear Fast Red staining
Tumour and lung slides were stained with 1% potassium hexacyano-ferrate (III)
trihydrate in 1% HCl for 30 minutes. Tissues were washed in dH2O prior to counterstain with
Nuclear fast red. Tissues were washed and dehydrated in increasing concentrations of 75%, 95%,
and 100% ethanol and xylene prior to being mounted.

2.2.2.8 Immunohistochemistry
Tumour and lung slides were rehydrated in 1X TBS-T (0.05M Tris Base, 1.8% NaCl,
0.05% Tween 20, pH 8.4). Tissues were blocked in for 30 minutes at room temperature in
Protein Block Serum-Free solution (Product no. X0909, Dako, Agilent Technologies, Glostrup,
Denmark). Tissues were then incubated in primary polyclonal antibody specific to NPY Y5R
(Cat no. ab137204, Abcam, San Francisco, CA, USA) diluted to 1:50 in 1% bovine serum
albumin, 1% normal goat serum, in TBS-T for 2hrs at room temperature. Adjacent slices were
incubated in TBS-T as a negative control. Tissues were washed three times and incubated in goat
anti-rabbit IgG (H+L) secondary antibody, Alexa Fluor® 568(Cat no. A-11011, Life
Technologies, Carlsbad, CA) diluted to 1:500 in 1% bovine serum albumin, 1% normal goat
serum, in TBST. Slides were washed prior to mounting and visualized with a fluorescence
microscope.

2.2.2.9 Statistics
Statistical analysis was performed using GraphPad software, data are presented as mean
± SEM. Non-linear regression analysis was performed on mean 3D tumour volume growths and
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signal void volumes to compare the cell lines. Statistical differences between treatments were
evaluated by two-way ANOVA, followed by Tukey's HSD test. The level of statistical
probability was set at p < 0.05.

2.3 Results
2.3.1 Y5R Presence and Localization in 67NR, 168FARN, and 4T1
Immunocytochemistry revealed receptor expression for Y5R in the 67NR, 168FARN,
and 4T1 cell lines (Figure 2.1). Primarily, nuclear staining was found in the 67NR and 168FARN
cell lines (Figure 2.1A&B). The 4T1 cell line displayed predominantly membranous and
cytoplasmic staining in addition to nuclear staining (Figure 2.1C).
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A.

Conjugate and Chromagen Control

B.

C.

Figure 2.1 Y5R Immunocytochemistry of 67NR, 168FARN and 4T1 Cells (A. 67NR)
Positive Y5R staining localized primarily in the nucleus (B. 168FARN) Positive Y5R staining
localized primarily in the nucleus (C. 4T1) Positive Y5R staining localized primarily in the
cytoplasm, membrane, and filapodia (Scale bars= 100µm). Conjugate and chromagen control
was conducted for each cell strain without incubation of the primary Y5R antibody,
demonstrating minimal background staining.
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2.3.3 Y5R Expression Quantified in 67NR, 168FARN, and 4T1
Western blots revealed significantly enhanced expression of Y5R in 4T1 cells compared
to 168FARN and 67NR cells (Figure 2.2). 4T1 expressed nine to twelve times greater levels of
Y5R than the 67NR and 168FARN cell lines, respectively.

Y5R (52kDa)

Figure 2.2 Basal Y5R Expression of Murine Mammary Fat Pad Carcinoma Cell Lines.
Western Blot densitometry quantification of respective cell lysates normalized to total protein
depicting the significantly enhanced Y5R expression of 4T1 cells compared to 168FARN and
67NR cells. Densitometric data are presented as Y5R expression normalized to total protein
expression. Data are presented as mean+ SE (n=3, ** represents a significant difference from
67NR cells p<0.01, One- way ANOVA).
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2.3.3 Effect of NPY on Proliferation of 67NR, 168FARN, and 4T1
The MTS proliferation assay demonstrated that NPY has a stimulatory effect on
proliferation of the three cell lines, despite variable basal Y5R expression. Without normalization
of NPY-stimulated proliferation to the respective basal cell strain proliferation, the cell lines had
a significantly different proliferative response to NPY (p<0.001) (Appendix A). The unstimulated proliferation of each cell line differed, supporting the normalization of experimental
proliferation to basal growth to appropriately investigate the effect of NPY-stimulated
proliferation. Experimental proliferation was normalized to basal growth by dividing
experimental proliferation by un-stimulated proliferation of the respective cell line, resulting in a
control growth of 1 for each cell line (Figure 2.3). Stimulated growth can be observed by values
greater than 1.0, denoted by the dashed line. When normalized to the control, the proliferation of
each cell line in response to NPY was not significantly different from each other (p>0.05, Twoway ANOVA). NPY concentration had a significant effect on the proliferation of the cell lines
(p<0.0001, Two- way ANOVA).
67NR and 168FARN cell proliferation was stimulated by NPY at 10-10M, 10-9, and 10-7M
(Appendix A). The proliferation appears to drop at concentrations greater than 10-7M. As
expected, the administered scrambled sequence of NPY, as a negative control, did not stimulate
proliferation of 67NR and 168FARNcells (Appendix A). The proliferation appears to plateau at
10-10M of NPY. 4T1 cell proliferation was strongly stimulated by all tested concentrations of
NPY, except 10-8M, with no apparent plateau in cell growth (Appendix A). The administered
scrambled sequence of NPY, as a negative control, did not stimulate proliferation of 4T1 cells.
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A.

B.

C.

Figure 2.3 NPY stimulates proliferation of 67NR, 168FARN, and 4T1 cell lines. NPY
treatment stimulated an increase in proliferation of all three cell lines at various concentrations
(NPY 10-11M-10-6M). (A. 67NR) A proliferative effect was stimulated by NPY at 10-10M, 10-9,
10-7M. (B. 168 FARN) A proliferative effect was stimulated by all tested concentrations of NPY
and a subtle stimulation by the scrambled form of NPY. (C. 4T1) A proliferative effect was
stimulated by all tested concentrations of NPY. (All values were statistically compared to
respective control cell growth, * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001, Oneway ANOVA).
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2.3.4 Effect of Y5R blockade on proliferation on 67NR, 168FARN, 4T1
To determine the specific contribution of Y5R activation in NPY-stimulated
proliferation, the effect of Y5R blockade by a Y5R- specfic antagonist (L-152804) was examined
by the MTS proliferation assay. Cells were incubated with media containing NPY (10-6 M) and
L-152804 (10-4 M). The data were compared to the proliferation of the cells at their peak
proliferation. 67NR and 168FARN cell proliferation was stimulated most at 10-9 M NPY and 4T1
cell proliferation was stimulated most at 10-6 M NPY. The Y5R antagonist restored the growth of
the cells to basal level in all three cell lines as depicted in Figure 2.4.
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A.

B.

C.

Figure 2.4 Y5R Blockade inhibits NPY stimulated proliferation of 67NR, 168FARN, and
4T1 cell lines. (A. 67NR) proliferation was significantly stimulated by 10-9M NPY (p<0.05).
NPY in conjunction with L-152 804 (10-4 M) restored proliferation to control. (B. 168FARN)
proliferation was significantly stimulated by 10-9M NPY (p<0.05). NPY in conjunction with L152 804 (10-4 M) restored proliferation to control. (C. 4T1) proliferation was significantly
stimulated by 10-6M NPY (p<0.05). NPY in conjunction with L-152 804 (10-4 M) restored
proliferation to control. (All values were statistically compared to respective control cell growth,
* denotes p<0.05, ** denotes p<0.01, One- way ANOVA).
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2.3.5 Establishing and validating 4T1 Y5R-Knockdown
A 4T1 Y5R-Knockdown (KD) was established previously as described above via
shRNA. Positive vector transfection was selected using flow cytometry to select for GFP+ cells.
7-AAD viability gating was applied to analyze solely viable cells. Side scatter gate was applied
to analyze solely single cells. Forward scatter gate was applied to confirm that cells were
analyzed and not debris of the same size. GFP+ gate was applied to analyze cells that expressed
GFP. Prior to the final flow cytometry sort, the GFP purity was evaluated at 98.1%. Post flow
cytometry sort, the GFP purity was evaluated at 98.7%. GFP+ purity with applied gates post
final sort is shown in Figure 2.5A.
Western blotting was conducted to confirm the knockdown and revealed a reduction of
51.67% in the expression of Y5R in the 4T1 Y5R-KD (n=6) compared to the 4T1 (n=6) cell line
as shown in Figure 5B. Figure 5C shows reduced Y5R expression in the 4T1 Y5R-KD cell line
in the membrane and cytoplasm compared to the 4T1 cell line.
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A.

GFP Expression Intensity

GFP Expression Intensity

B.
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C.

4T1

4T1 Y5R-KD

Figure 2.5 shRNA Y5R Specific Knockdown Decreased Y5R Expression (A. Flow
Cytometry) 4T1 Y5R KD achieved via shRNA sorted via flow cytometry with a purity of 98.7%
GFP+. 7-AAD viability gate, side-scatter gate, forward scatter gate and final GFP+ gate applied.
(B. Western Blot) Densitometry quantification of 4T1 and 4T1 Y5R KD cell lysates normalized
to total protein depicting the significantly reduced Y5R expression of 4T1 Y5R KD cell line
compared to the 4T1 cell line. Densitometric data are presented as Y5R expression normalized to
total protein expression discerned from Coomassie blue staining average lane intensity. Data are
presented as mean+ SE (n=6, *** represents a significant difference from 4T1 cell line p<0.001,
un-paired t-test). (C. Immunocytochemistry of 4T1 and 4T1 Y5R KD) Immunocytochemistry
of 4T1 and 4T1 Y5R KD cells with decreased cytoplasmic Y5R expression (Scale bar=100µm).
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2.3.6 Effect of NPY on Proliferation of 4T1 and 4T1 Y5R-KD
An MTS assay was conducted on the 4T1 and 4T1 Y5R-KD cell line to elucidate the
proliferative effect that NPY would have on the newly developed strain with a diminished Y5R
expression. The MTS Assay revealed 4T1 and 4T1 Y5R-KD cell strains proliferate at similar
rates in the absence of NPY as shown by the control in Figure 6A. As a negative control, a
scrambled sequence of NPY was applied to both 4T1 and 4T1 Y5R-KD cell lines. The scrambled
NPY sequence did not induce proliferation of the 4T1 and 4T1 Y5R-KD cell lines as shown in
Figure 2.6A. This is expected as scrambled NPY does not activate targeted NPY receptors. 4T1
and 4T1 Y5R-KD cells responded significantly different to NPY stimulation (p<0.05, Two- way
ANOVA). 4T1 cells achieved a plateau of proliferation at 10-10 M NPY as shown in Figure 2.6B.
In contrast, the 4T1 Y5R-KD cell line requires a greater concentration of 10-7 M NPY, for cell
proliferation to plateau as shown in Figure 2.6C. There is a significant difference in proliferation
between 4T1 and 4T1 Y5R KD cells at concentrations of 10-10 M (p<0.05), 10-9 M (p<0.05), 10-8
M (p<0.05), and 10-6 M (p<0.05) as shown in Figure 2.6A(p<0.05, Two way ANOVA). 4T1
Y5R-KD cell proliferation is stimulated solely at 10-7 M (p<0.05) as shown in Figure 2.6C,
compared to 4T1 cells that proliferate at 10-10 M (p<0.05), 10-9 M (p<0.05), 10-7 M (p<0.01), and
10-6 M (p<0.01) as shown in Figure 2.6B. Therefore, 4T1 Y5R-KD requires more NPY to
enhance proliferation compared to 4T1 cells.
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Figure 2.6 MTS Assay of 4T1 and 4T1 Y5R-KD with NPY stimulation (10-11-10-6M) (A. 4T1
and 4T1 Y5R-KD proliferation) MTS Proliferation Assay demonstrated that without NPY
stimulation, there is no significant difference in proliferation between 4T1 and 4T1 Y5R KD
cells. 4T1 and 4T1 Y5R-KD cells proliferate significantly differently in response to NPY
(p<0.05). The cell line accounted for 40.81% of variation of proliferation in response to NPY
(p<0.05, Two way ANOVA with repeated measures, n=3). Concentration accounted for 26.91%
of variation of proliferation in response to NPY (p<0.01, Two way ANOVA with repeated
measures, n=3). There was a significant difference in proliferation between 4T1 and 4T1 Y5R
KD cells at concentrations of 10-10 M (p<0.05), 10-9 M (p<0.05), 10-8 M (p<0.05), and 10-6 M
(p<0.05, Two way ANOVA with repeated measures, n=3). (B. 4T1) MTS Proliferation Assay
demonstrated that NPY has a stimulatory effect on proliferation 4T1 cells at concentrations of
10-10 M (p<0.05), 10-9 M (p<0.05), 10-7 M (p<0.01), and 10-6 M (p<0.01) of NPY compared to
un-stimulated 4T1 cells (One-way ANOVA with repeated measures, n=3). (C. 4T1 Y5R-KD)
NPY stimulated proliferation of 4T1 Y5R-KD cells solely at a concentration of 10-9 M compared
to un-stimulated 4T1 Y5R-KD cells (One-way ANOVA with repeated measures, n=3).
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2.3.7 Effect of Y5R blockade on proliferation on 4T1 and 4T1 Y5R-KD
The effect of Y5R blockade by a Y5R- specfic antagonist (L-152804) was examined by
the MTS proliferation assay. Cells were incubated with media containing NPY (10-6 M) and L152804 (10-4 M). The Y5R antagonist restored the growth of the cells to basal level in 4T1 cells
as shown in Figure 2.7A. There was no significant difference in the proliferation of 4T1 Y5RKD cells between control, maximal NPY- stimulated proliferation and maximal NPY in
conjunction with L-152804 as shown in Figure 2.7B.

A.

B.

Figure 2.7 MTS Assay of 4T1 and 4T1 Y5R-KD with NPY and Y5R Antagonism. (A. 4T1)
Proliferation was significantly stimulated by 10-6M NPY (p<0.05). NPY in conjunction with L152 804 (10-4 M) restored proliferation to control. (B. 4T1 Y5R-KD) There was no significant
difference between treatments in 4T1 Y5R-KD cells (All values were statistically compared to
respective control cell growth, * denotes p<0.05, One- way ANOVA).
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2.3.8. Iron oxide labeling of 4T1 and 4T1-Y5R KD cells for injection
Prior to orthotopic injection, 4T1 and 4T1 Y5R-KD cells were pre-labeled with MPIOs to
track proliferative status via iron dilution. The large iron oxide nanoparticle size permits single
cell tracking with MRI. Figure 2.8 shows iron oxide nanoparticles stained with Perls’ Prussian
Blue and cell nuclei stained with Nuclear Fast Red of 4T1 cells (Figure 2.8A) and 4T1 Y5R-KD
cells (Figure 2.8B). Qualitatively, as seen in Figure 2.8, it appears that both 4T1 and 4T1 Y5RKD cells were nearly all labeled, prior to injection.

A.

B.

Figure 2.8 PPB and NFR Staining of 4T1 and 4T1 Y5R-KD Cells (A. 4T1) Nuclei stained
with Nuclear Fast Red and iron oxide nanoparticles stained with Perl’s Prussian Blue of cells
injected for MR imaging (B. 4T1 Y5R-KD) Nuclei stained with Nuclear Fast Red and Iron oxide
nanoparticles stained with Perl’s Prussian Blue of cells injected for MR imaging.
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2.3.9 In vivo mammary fat pad tumour appearance and volumes
BALB/c mice were imaged on days 7, 14, 21 and 28 with the bSSFP imaging sequence.
4T1 and 4T1 Y5R-KD cells were pre-labeled with MPIOs to allow for tracking cells and
monitoring proliferation in vivo; as cells proliferate the iron is diluted between daughter cells to a
level below the sensitivity of MRI. The fraction of iron at each time point can be compared
between the two cell lines to estimate patterns and degree of in vivo cell proliferation.
Figure 2.9 shows representative MR images of the mouse body at day 14 post 4T1 cell
injection. The locations of the mammary fat pad tumour are outlined in green. Isovolumetric
voxels permit visualization of the tumour in the sagittal, coronal and axial orientations without
distortion. Figure 2.10 shows similar images for a mouse that received 4T1 Y5R KD cells. In
both subject groups, signal loss appears within the primary tumour.
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Figure 2.9 MR Appearance of 4T1 MPIO Pre-labelled Mammary Fat pad Tumour at Day
14. (A. Sagittal view) H-head, T-tail, B-back, white arrows- lungs, white arrow head- liver, blue
arrow- muscle. (B. Coronal view) H-head, T-tail, L-left, R-right, white arrow- lung, white arrow
head- liver. (C. Axial view) Orange arrow head-spine. Tumour is outlined in green in all images.
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Figure 2.10 MR Appearance of 4T1 Y5R-KD MPIO Pre-labeled Mammary Fat Pad
Tumour at Day 14. (A. Sagittal view) H-head, T-tail, B-back, white arrow head- liver, blue
arrow- muscle, blue arrow head-spleen. (B. Coronal view) H-head, T-tail, L-left, R- right,
white arrow- lung, white arrow head- liver, blue arrow-muscle, orange arrow- lymph node. (C.
Axial view) Orange arrow head-spine. Tumour is outlined in green in all images.
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2.3.10 Longitudinal MRI of primary tumour
Figure 2.11 and 2.12 show representative cropped images of the 4T1 and 4T1 Y5R-KD
primary mammary fat pad tumours, respectively, at each imaging time point and the
corresponding signal intensity colour maps. In the colour maps, blue represents regions of signal
hypointensity (due to iron oxide particles), yellow represents regions of hyperintense signal (due
to fluid accumulation) and green represents intermediate signal intensities (tumour mass). In all
mice the tumour size increased over time.
For all mice with 4T1 tumours (Figure 2.11), a large region of low signal intensity was
observed in the central part of the tumour at day 7. Iron appears with low signal intensity in
bSSFP images, therefore, this observation suggests the presence of iron retaining cells in the
tumour. Over time, as the tumour increased in size this region of central signal loss decreased in
size. In images acquired on day 28 subtle regions of signal hyperintensity were apparent in all
tumours. Fluids appear bright in bSSFP images, therefore, these regions suggest that there is
accumulation of fluid, possibly due to necrosis, in tumours at this timepoint.
Images of 4T1 Y5R-KD tumours showed some differences compared to 4T1 tumours
(Figure 2.12). Signal loss was again observed in images of the 4T1 Y5R-KD tumours at day 7,
however, the signal loss was not restricted to the central zone of the tumour. Instead signal loss
was observed distributed throughout the tumour mass. In addition, the total volume of signal
loss was less in 4T1 Y5R-KD tumours compared to 4T1. Over time, this pattern of signal loss
persisted. As with 4T1 tumours the region of signal loss decreased over time. In one of the five
4T1 Y5R-KD mice no signal loss could be detected in the day 28 image of the tumour. In images
acquired on day 28 regions of signal hyperintensity became apparent. A larger amount of the 4T1
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Y5R-KD tumours were occupied by signal hyperintensity as compared to 4T1 tumours (Figure
2.13).
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Day 7

Day 14

Day 21

Day 28

Figure 2.11 4T1 Mammary Fat Pad Tumours. MR image and colour map, respectively, of a
MPIO pre-labeled tumour at days 7, 14, 21, and 28.
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Day 7

Day 14

Day 21

Day 28

Figure 2.12 4T1 Y5R KD Mammary Fat Pad Tumours. MR image and colour map,
respectively, of a MPIO pre-labeled tumour at days 7, 14, 21, and 28.
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4T1

4T1 Y5R-KD

Figure 2.13 Representative 4T1 and 4T1 Y5R-KD tumours at Day 28 Highlighting
Differences in Amount of Signal Hyperintensity. At day 28, the 4T1 Y5R-KD tumours has
larger regions of signal hyperintensity compared to 4T1 tumours. Regions of hyperintensity are
represented with yellow. Green represents intermediate signal intensity and blue represents
signal hypointensity.

61

2.3.11 Volumes of the primary tumour and signal void regions
bSSFP images were collected in 3D, permitting measurement of tumour volume (Figure
2.14). The tumour volumes measured for the 4T1 and the 4T1 Y5R-KD cell lines were not
significantly different at days 7, 14, and 21 between cell lines. At day 28 post- cell injection, the
mean 4T1 tumour volume was significantly greater than the mean 4T1Y5R KD tumour volume
(p<0.001, Two way ANOVA). This suggests that the tumourigenicity of the two cell lines is
significantly different (p<0.05, Two way ANOVA). The tumour growth was modeled with an
exponential equation (Y=Y0 * ek-x ) for the 4T1 cell line (Y0=0.05261, k=0.1113) and the 4T1
Y5R-KD cell (Y0=0.04209, k=0.1112).
At day 7, the percentage of the tumours occupied by signal loss was significantly greater
in 4T1 tumours (16.56+7.89) compared to 4T1 Y5R-KD tumours (8.29+2.48) (p<0.001). This
was not significantly different at days 14, 21, and 28 (Figure 2.15). The change in signal loss
over time between the two cell lines is significantly different (p<0.01, Two way ANOVA). A
one-phase decay (Y=Y0 –plateau*e-kx + plateau) was fit to the 4T1 cell line signal void volume
normalized to tumour volume (Y0 =86.35, plateau=1.19, K=0.2446, R2 =0.7704) and the 4T1
Y5R-KD cell line signal void volume normalized to tumour volume (Y0 =20.11, plateau=0.7975,
K=0.1354, R2 =0.7116).
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Figure 2.14 Mean 3D Tumour volume from MRI. The average tumour volume for the 4T1
and the 4T1 Y5R-KD cell lines were not significantly different at days 7, 14, and 21. 4T1 Y5R
KD tumours were significantly smaller than 4T1 tumours at day 28 (p<0.001, Two way
ANOVA). Tumourigenicity of the two cell lines is significantly different (p<0.05, Two way
ANOVA). Tumour growth was modeled with an exponential equation (Y=Y0 * ek-x ) for the 4T1
cell line (Y0=0.05261, k=0.1113) and the 4T1 Y5R-KD cell (Y0=0.04209, k=0.111)
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Figure 2.15 Signal Void Volume Normalized to Tumour Volume. Signal void volume
normalized to tumour volume was significantly greater in 4T1 tumours than 4T1 Y5R-KD
tumours at day 7. The iron void volume normalized to tumour volume of the 4T1 cell line and
the 4T1 Y5R-KD cell line was not significantly different at days 14, 21, and 28 (Figure 12). The
dilution of iron between the two cell lines is significantly different (p<0.01, Two way ANOVA).
A one-phase decay (Y=Y0 –plateau*e-kx + plateau) was fit to the 4T1 cell line iron void volume
normalized to tumour volume (Y0 =86.35, plateau=1.19, K=0.2446, R2 =0.7704) and the 4T1
Y5R-KD cell line iron void volume normalized to tumour volume (Y0 =20.11, plateau=0.7975,
K=0.1354, R2 =0.7116).
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2.3.12 Images of Metastases
Both lung and lymph node metastases were observed using MRI. Lung metastases were
observed in both 4T1 and 4T1 Y5R-KD mice. MRI detectable lung metastases were observed as
early as 21 days post cell implantation in 4T1 mice and in images acquired on day 28 in 4T1
Y5R-KD mice. Lung metastases were visible as regions of signal hyperintensity in the lung,
which normally appears black in MR images because of air. At day 21, 3 of 4 4T1 mice had
MRI detectable lung metastases. By day 28, all 4T1 mice had visible lung metastases. At day
28, 3 of 5 4T1 Y5R-KD mice had MRI detectable lung metastases. Lung metastases appeared
larger in 4T1 mice. Representative images of lung metastases are shown in Figure 2.16.
Metastases in lymph nodes were only observed in mice that received the 4T1 Y5R-KD
cells. Nodal metastases were detected in images of 3 of the 5 mice (Figures 2.17-2.19).
Metastases were detected in either the contralateral or ipsilateral axillary node and in the
ipsilateral inguinal node. In Figure 2.17 an axillary node metastasis is shown on the contralateral
side to the primary tumour (yellow arrow). Images are shown in all three orientations. In
Figure 2.18 an axillary node metastasis is shown on the ipsilateral side to the primary tumour
(yellow arrow). This metastasis has two lobes. In Figure 2.18 an inguinal node metastasis is
visible near the primary tumour. This metastasis is of particular interest since it contains a
distinct region of signal void. Unfortunately in this study the nodes were not recovered for
histological assessment.
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Figure 2.16 MR Images of Representative Lung Metastases. Sagittal image slices of mice
bodies showing MRI detectable lung metastases (white arrow) as regions of signal hyperintensity
on black lungs (A. 4T1, day 21) Representative lung metastases found in 3 of 4 4T1 mice at day
21. (B and C. 4T1, Day 28) Representative lung metastases found in all 4 4T1 mice at day 28.
(D. 4T1 Y5R-KD, day 21) Representative lung images demonstrating lack of metastases at day
21 in 4T1 Y5R-KD mice. (E and F. 4T1 Y5R-KD, Day 28) Representative lung metastases
found in 3 of 5 4T1 mice at day 28.
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A.

B.

C.

Figure 2.17 MR Images of Contralateral Axillary Lymph Node in 4T1 Y5R-KD Mouse at
Day 28. (A. Coronal view) Enlarged axillary lymph node (white arrow) (B. Axial view) Enlarge
axillary lymph node (white arrow) (C. Sagittal view) Enlarged contralateral axillary lymph node
(white arrow) with heterogeneous mammary fat pad 4T1 Y5R-KD primary tumour (yellow
arrow) with speckled signal voids and necrotic core.
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A.

B.

C.

Figure 2.18 MR Images of Ipsilateral Axillary Lymph Node in 4T1 Y5R-KD Mouse at Day
28. (A. Coronal view) Enlarged axillary lymph node with two lobes (white arrows) (B. Axial
view) Enlarge axillary lymph node (white arrow) (C. Sagittal view) Enlarged ipsilateral axillary
lymph node (white arrow) with heterogeneous mammary fat pad 4T1 Y5R-KD primary tumour
(yellow arrow) with speckled signal voids and necrotic core.
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A.

B.

C.
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Figure 2.19 MR Images of Inguinal Lymph Node in 4T1 Y5R-KD Mouse at Day 28. (A.
Coronal view) Inguinal lymph node with distinct signal void (white arrow) (B. Axial view)
Inguinal lymph node with distinct signal void (white arrow) (C. Sagittal view) Inguinal lymph
node with distinct signal void (white arrow) neighbouring heterogeneous mammary fat pad 4T1
Y5R-KD primary tumour (yellow arrow) with hypointense ulceration.
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2.3.13 Histology of primary tumours
Primary mammary fat pad tumours were sectioned and stained with H&E and PPB&NFR
to visualize tumour morphology and identify iron oxide nanoparticle localization, respectively.
Tumors from both cell lines had similar histological appearances. Figure 2.20 shows
representative H&E stained sections of 4T1 and 4T1 Y5R-KD tumors at Day 28. Examination of
the tumors revealed that they frequently contained regions of low cell density, consistent with the
heterogeneous signal in MR images. Signal hyperintensity in bSSFP images represents the
presence of fluid or fat accumulation, as previously shown in Figure 2.13. Examination of H&E
revealed necrotic zones in both tumour types.
Figure 2.21 shows representative PPB stained sections of 4T1 and 4T1 Y5R-KD tumors
at Day 28. Figures 2.21A-C shows the PPB-positive cells in a section from a 4T1 tumour and the
corresponding mouse MRI. PPB-positive cells were typically located centrally within the
tumour section, which agreed well with observations from MRI (2.21C). Figure 2.21D&E show
PPB staining in a section from a 4T1 Y5R-KD tumour at day 14 and the corresponding MRI.
PPB staining was rarely observed in the small sample of day 28 4T1 Y5R-KD tumour sections
we examined.
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Figure 2.20 Representative H&E of 4T1 and 4T1 Y5R-KD primary tumours with necrosis
at Day 28. Necrosis (denoted by black arrows) was found in both 4T1 and 4T1 Y5R-KD
tumours at Day 28. (A and B.) H&E of 4T1 tumour. Scale bar for A= 300µm. Scale bar for B=
200µm (C and D.) H& E of 4T1 Y5R-KD tumour. Scale bar for C= 300µm. Scale bar for D=
200µm
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A.

B.

D.

E.

C.

Figure 2.21 Representative PPB and NFR of 4T1 and 4T1 Y5R-KD Primary Tumours with
Corresponding MR images. (A and B. 4T1 PPB&NFR) Iron appears blue with PPB staining.
A&B show positive PPB staining in a 4T1 tumour at Day 28 which is concentrated at the core of
the tumour. Scale bar for A= 50µm. Scale bar for B= 200µm (C.4T1 MR) Sagittal MR image
depicting hypointensity concentrated at the core of the tumour. Tumour is outlined in green. (D.
4T1 Y5R-KD PPB&NFR) Positive PPB staining in a 4T1 Y5R-KD tumour at Day 14. Scale bar
for C= 200µm. (E. 4T1 Y5R-KD MR) Sagittal MR image depicting hypointensity distributed
throughout the tumour. Tumour is outlined in green.
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2.3.14 Y5R Immunohistochemistry of primary tumour
Immunohistochemistry (IHC) was conducted on tumours resected at days 14, 21, and 28
in the 4T1 Y5R-KD model and at day 28 in the 4T1 model to evaluate the contribution of Y5R to
tumour development. Optimization IHC was conducted on control BALB/c brains and the
negative control, without the Y5R primary antibody, displayed no observable fluorescence
(Appendix B). Figure 2.22A shows subtle Y5R expression at the edge of the tumour in the 4T1
Y5R-KD model at day 14, there is no observable Y5R expression in the core of the tumour at
this time point. Figure 2.22B shows a diffuse distribution of Y5R in the 4T1 Y5R-KD model at
day 21 throughout the tumour with enhancement at the edge of the tumour. Figure 2.22C shows a
homogeneous distribution of Y5R in the 4T1 Y5R-KD tumour at day 28 with subtle
enhancement at the edge of the tumour. Figure 2.20C Y5R in the 4T1 Y5R-KD model at day 28
is comparable to the Y5R expression in the 4T1 model at day 28 in Figure 2.22D. The 4T1
tumour at day 28 has high Y5R expression throughout the tumour and is enhanced at the tumour
edge.
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Figure 2.22 Y5R-IHC of primary MFP tumour. (A. 4T1 Y5R-KD day 14) Subtle
fluorescence at edge of tumour. (B. 4T1 Y5R-KD day 21) Diffuse fluorescence throughout the
tumour compared to the edge. (C. 4T1 Y5R-KD day 28) Enhanced Y5R fluorescence
distributed throughout the tumour. (D. 4T1 day 28) Y5R fluorescence present throughout the
tumour and emphasized at the edge of the tumour.
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2.3.15 Histology of Lung Metastases
Lungs were stained with Hematoxylin and Eosin (H&E) to evaluate metastatic burden
from the primary MFP tumour. Fluorescent immunohistochemitry, targeting Y5R, was
conducted to qualitatively assess the expression of Y5R in lung metastases. Figure 2.23 shows
matched H&E and Y5R IHC of a metastasis in the 4T1 model. In figure 2.23A, Y5R IHC
revealed less Y5R fluorescence in the metastasis, compared to surrounding Y5R fluorescence of
lung parenchyma. Figure 2.23C reveals that the Y5R fluorescence of this metastasis is
comparable to the Y5R fluorescence to the surrounding lung parenchyma.
Figure 2.24A and B show matched H&E and Y5R IHC of a metastasis in the 4T1 Y5RKD model. Similar to the 4T1 model, Y5R IHC revealed some metastases, which possessed less
Y5R fluorescence, compared to surrounding Y5R fluorescence of lung parenchyma (2.24A). The
MRI of this lung is shown in Figure 2.24C. Figure 2.24D depicts a metastasis situated near a
vessel. The matched Y5R IHC reveals in Figure 2.24E that this metastasis has similar
fluorescence to surrounding Y5R fluorescence of the lung parenchyma. As qualitatively assessed
by immunohistochemistry, metastases from both 4T1 and 4T1 Y5R-KD tumours had less or
similar Y5R expression in comparison to the high expression of Y5R in lung parenchyma.
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A.

C.

B.

D.

Figure 2.23 4T1 Lung Metastases at Day 28. All metastases are denoted by arrows.
Representative H&E and matched Y5R IHC of metastases in lungs (Scale bars=200µm) (A.)
H&E displays lung metastases (B.) Matched Y5R IHC to A. demonstrates less Y5R expression
in the metastases in contrast with surrounding high Y5R expression in lung parenchyma. (C.)
H&E displays lung metastases and (D.) Matched Y5R IHC to C. demonstrates equal Y5R
expression in the metastases in contrast with surrounding high Y5R expression in lung
parenchyma.
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Figure 2.24 4T1 Y5R-KD Lung Metastases at Day 28. All metastases are denoted by arrows.
(Scale bars=200µm) (A.) H&E stained lung tissue (B.) Matched Y5R IHC to A. demonstrates
less Y5R expression in the metastases in contrast with surrounding high Y5R expression in lung
parenchyma. (C.) Representative MRI of lung metastases. (D.) H&E displays lung metastases
adjacent to a vessel (arrowhead) and (E.) Matched Y5R IHC to D. demonstrates enhanced Y5R
expression in the metastases in contrast with surrounding Y5R expression in lungs.
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2.3.16 Recovery of Y5R in 4T1 Y5R-KD in vitro
4T1 and 4T1 Y5R-KD cells were grown for 28 days in vitro to evaluate the stability of
the 4T1 Y5R-KD. Western blotting was conducted on 4T1 and 4T1 Y5R-KD cell lysates. Cells
were analyzed after their seventh passage for Y5R expression. Band intensity was evaluated
using densitometry and was normalized to the average lane intensity with Coomassie blue
membrane staining. Figure 2.24 demonstrates that 4T1 and 4T1 Y5R-KD cells did not have
significantly different Y5R expression after 28 days of growth in vitro (p>0.05, Unpaired t-test).

Figure 2.25 Western Blot densitometry quantification of 4T1 and 4T1 Y5R KD cell lysates
normalized to total protein depicting the no significant difference in Y5R expression between the
4T1 and 4T1 Y5R-KD cell line. Densitometric data are presented as Y5R expression normalized
to total protein expression discerned from Coomassie blue staining average lane intensity. Data
are presented as mean+ SE (n=3).
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2.3.4 Discussion
Understanding the interactions between tumour cells and their microenvironment that
enhance carcinogenesis and metastases is key to new paradigms for treating cancer. This study is
the first to our knowledge that has illustrated the variable expression of the Neuropeptide Y5
Receptor (Y5R) to coordinate with the varying metastatic potential of different breast cancer
models. Furthermore, this is the first study to reveal the potential role of cytoplasmic localization
of Y5R in a breast cancer cell strain with the propensity to metastasize. Using cellular MRI, this
study has shown the contribution of Y5R in vivo on tumourigenicity and metastasis in an
immune competent model.
The 4T1-derived murine mammary carcinoma cell lines are syngeneic immune
competent models and thereby permit a biologically relevant evaluation of cancer. Identification
of specific biomarkers indicative of metastatic ability would be ideal to determine the fate and
risk potential of cancer cells. The Jackson lab has previously confirmed the presence of Y5R in
the 4T1 cell line.22 In this study, immunocytochemistry confirmed that Y5R is expressed in the
67NR, 168FARN, and 4T1 cell lines, providing the impetus to quantify the expression of Y5R in
the respective strains with Western blot analysis. As hypothesized, metastatic 4T1 breast cancer
cells expressed significantly more Y5R than non-metastasizing 67NR and 168FARN cell lines.
This finding suggests that the expression of Y5R coordinates with metastatic potential of breast
cancer strains. Sheriff et al. have also found Y5R in estrogen receptor positive and negative
human breast carcinoma cell lines, demonstrating the potential role of Y5R in both estrogen
receptor positive and negative models.27
Despite variable expression of Y5R in each of the cell strains, Neuropeptide Y
significantly stimulated proliferation of all three studied breast cancer cell lines. This finding
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demonstrates the robust mitogenic properties of Neuropeptide Y. Stressful conditions, such as
cold or restraint stress, significantly enhance the circulating plasma levels in mice from basal
levels of the order 10-11 M to approaching 10-10 M in stress conditions.28 Additionally, the
Jackson lab has demonstrated robust NPY expression in sympathetically innervated 4T1
mammary fat pad tumours.29 Further studies should be conducted in vivo, to elucidate if NPY is
sufficient to accelerate proliferation of the slowly proliferating 67NR cell strain in basal and
stressed conditions.
Previous experiments have demonstrated that Neuropeptide Y in conjunction with Y1R
or Y2R antagonism does not inhibit proliferation in 4T1 cells, in contrast to Y5R antagonism,
which abolishes Neuropeptide Y stimulated proliferation.22 Y5R antagonism has also been
shown to abolish the proliferative effect of NPY in triple negative human breast carcinoma BT549, estrogen positive human breast carcinoma MCF-7, and SK-N-BE2 neuroblastoma.27,30
Similarly, this study demonstrated that Y5R antagonism eliminated the proliferative effects of
Neuropeptide Y of the 67NR, 168FARN and 4T1 cell line.
In a previous study by the Jackson lab examining the pro-angiogenic effects of NPY on
the 4T1 breast cancer cells, twenty four hours of NPY treatment caused a marked increase in
VEGF expression in 4T1 cells compared to non- treated controls, as a negative control,
scrambled NPY treatment had no effect on VEGF expression.21 As well, in a study of various
human breast carcinoma cell lines in vitro, no NPY mRNA could be detected.27 These findings
suggest that 4T1 cells require the stimulation of NPY released from sympathetic nerves to induce
Y5R-mediated cancerous properties.
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Traditionally, GPCRs were considered to reside solely in the cell membrane and elicit
their effect downstream through secondary effectors, however this notion has been dismissed
with effects and localization in the nucleus. In fetal and embryonic endothelial cells, active Y1R
has been found predominantly in the nucleus and nuclear envelope compared to the cytoplasm,
with the capacity to induce an increase in nuclear Ca2+ upon NPY stimulation, suggesting a
potential nuclear role in gene expression modulation.31 In a study by Czarnecka et al., brainderived neurotrophic factor (BDNF) increased Y5R expression and triggered internalization of
Y5R in neuroblastoma cells as a pro-survival technique against cellular stress such as
chemotherapy. Y5R antagonism inhibited chemo-resistance and sensitized the cells to apoptosisinduced chemotherapy.18
As shown with immunocytochemistry, we found Y5R is expressed predominantly in the
cytoplasm and membrane in the aggressively metastasizing 4T1 breast cancer strain. In contrast,
we found that non-metastasizing 67NR and 168FARN breast cancer strains express Y5R
predominantly in the nucleus. The significance of nuclear Y5R localization requires further
investigation. The nuclear Y5R localization of 67NR and 168FARN cells could support
chemoresistance of breast cancer cells, similar to neuroblastoma.18 If basal nuclear receptor
internalization of the non-metastatic strains mediates inhibition of pro-cancerous genes,
therapeutic monoclonal Y5R antibodies that induce internalization could be therapeutic for
metastatic strains. Anti- EGFR and anti- HER2 antibodies that induce receptor internalization
have been approved for clinical use in oncology.32 Receptor localization of the 67NR and
168FARN strains post NPY stimulation should be further investigated to understand the role of
receptor localization. The nuclear Y5R localization of 67NR and 168FARN cells could support
chemoresistance of breast cancer cells, similar to neuroblastoma.18 Additionally, the capacity of
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67NR cells to proliferate under certain concentrations of NPY may modulate tumour- supporting
mitogenic genes to enhance proliferation via nuclear Y5R activation. It should be noted that in
human breast carcinoma cell line, BT-549 and rat aortic vascular smooth muscle cells, Y5R
activation was found not be coupled with a change in intracellular Ca2+.27,33 However, NPY and
Y5R specific agonism inhibits intracellular cAMP accumulation and correlates with proliferation
of BT-549 cells.27
MRI has been widely used to study preclinical mouse models of cancer and provides
excellent 3D anatomic detail and sensitivity to permit tumour size quantification and location, in
addition to edema, hemorrhage, and necrosis.24 The analysis of volumes over time can provide
information about growth rates for individual tumors. Cellular MRI can be achieved by prelabeling cells with iron oxide nanoparticles prior to their administration. In this study, we prelabelled 4T1 and 4T1 Y5R-KD cells with MPIOs. Labeling with MPIOs has been previously
shown to have no discernable effect on viability, in vitro proliferation, cell apoptosis, necrosis, or
in vivo metastasis compared to unlabeled cells.23–25
Few groups have used cellular MRI to study cancer cells because the iron label is diluted
over time in proliferative cells. Since the detection of iron-labeled cells by MRI relies on the
total iron content, eventually the cancer cells will not contain enough iron to be detected as
signal voids in MRI.

This property can be exploited, however, as slowly-proliferative or

transiently dormant cells retain iron oxide nanoparticles for longer periods of time than highly
proliferative cells.26 The Foster lab has previously used cellular MRI to monitor the development
of iron-labeled primary MDA-MB-231 mammary fat pad tumours and metastasis to the lymph
nodes.26
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Similarly, in this thesis we used cellular MRI to monitor the development of iron-labeled
primary 4T1 and 4T1 Y5R-KD mammary fat pad tumours and metastasis to the lungs and lymph
nodes. 4T1 Y5R-KD tumours grew significantly slower over four weeks and were significantly
smaller than 4T1 tumours at day 28. It is noteworthy that the significant difference in tumour
growth was under the influence of basally released NPY in non- stressed conditions. This
significant finding highlights the ability of NPY to activate Y5R, resulting in the acceleration of
in vivo tumour development, independent of chronic or traumatic stress.
The Foster lab has previously shown that proliferative status of cancer cells can be
evaluated through MRI through the retention of iron oxide nanoparticles.23,26 In this study, prelabeling 4T1 and 4T1- Y5R KD cells prior to implantation permitted evaluation of signal void
volume and distribution. We found 4T1 Y5R-KD tumours had a significantly smaller signal void
volume than 4T1 tumours at day 7. The presence of iron-labeled cells causes signal loss in MR
images and what is known as a blooming artefact, where the signal void volume is greater than
the actual volume occupied by iron oxide labeled cells.24 The size of the blooming artefact
depends on several factors including the total iron content, spatial resolution, magnetic field
strength, cell type and cell density. The larger void volume measured for 4T1 tumours compared
to 4T1 Y5R-KD tumours may be due to higher iron content in the tumour.
The distribution of iron- retaining cells also differed between the two cell lines. The 4T1
Y5R-KD tumours have a speckled or diffuse distribution of signal voids throughout the tumour,
in contrast to the centralized signal void in the core of 4T1 tumours.

Cells with similar

properties tend to remain clustered within tumours.34 This property could account for the
centralized cluster of slowly proliferating cells in the core of the 4T1 tumour. Furthermore, this
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property could account for the diffuse clustered aggregation of slowly proliferating iron-retaining
4T1 Y5R-KD cells that have maintained the knockdown.
Using MR imaging, we were able to detect metastases and enlargement of the axillary
and inguinal lymph nodes in only the 4T1 Y5R-KD mice. The presence of metastases in lymph
nodes is supported by distinct hypointensity in the inguinal lymph node due to the presence of
iron oxide nanoparticles disseminated from the primary tumour. Despite the presence of lymph
node metastases, lung metastases were detected in more 4T1 mice and at an earlier imaging time
point compared to 4T1 Y5R-KD mice. 4T1 cells metastasize primarily hematogenously and to a
lesser extent via draining lymph nodes.20 The non-metastatic 168FARN cell line spreads to the
lymphatics with occasional lung metastases.20 This finding suggests the knockdown of Y5R in
the 4T1 cell line has the capacity to diminish its aggressive metastatic phenotype to resemble the
non-metastatic 168FARN cell line.
Lungs are the most common site of breast cancer metastasis.35 NPY is released directly to
lungs and has the capacity to elevate pulmonary vascular permeability.36,37 The molecular
transduction of stress via NPY as a result of enhanced tumour burden should be further explored
as it may prime the microenvironment for targeted metastasis. This avenue is worth investigation
due to the high expression of Y5R in the lungs shown with immunohistochemistry. Y5R could
be an indicator of metastases onset and may play a role in metastases formation.
The tumour microenvironment at the edge differs from the hypoxic core of the tumour.
Particularly, tumour associated macrophages (TAMs) play a large role at the invasive edge of
tumours, to drive invasive phenotypes by stimulating cancer cell migration, metastasis, and
neovascularization.38 As we have shown with cellular MRI, 4T1 tumours possess an enhanced
fraction of slowly proliferating iron- retaining cells in the core of the tumour with more
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aggressively proliferative cells at the oxygenated tumour edge, permitting tumour expansion.
This property corresponds with the enhanced Y5R expression at the edge of the tumour depicted
in the immunohistochemistry. This finding suggests that the expansion of the primary tumour is
mediated by the NPY-Y5R system. As the tumour develops, the formation of the hypoxic core
supports the mitogenic properties of NPY, as hypoxia activates DPPIV driving Y2R/Y5R
mediated tumourigenesis as previously established in Ewing sarcoma.19
The complete contribution of Y5R to tumour development and metastasis is diminished
with the 4T1 Y5R-KD model due to the recovery of the receptor over time as shown with
immunohistochemistry. The knockdown of Y5R, as shown with Western blot and ICC, at the
initial establishment of the cell line, could contribute to the delayed tumour development,
resulting in a significant decrease in the 4T1 Y5R-KD tumour volume at day 28. If the
knockdown has the capacity to significantly impede proliferation of 4T1 cells, the subpopulation
of Y5R+ cells has the opportunity to out-compete the knockdowns. This issue is further
compounded with in vitro passaging of cells, where a greater fraction of highly proliferative
cells would be consequently plated. Given that shRNA achieved a 51% reduction in Y5R, which
was then recovered over time, this may suggest that Y5R+ positive cells in the 4T1 Y5R-KD
model could have driven establishment of metastases.
Overall, we report the variable presence and expression of Y5R in the 67NR, 168FARN
and 4T1 murine breast cancer cell strains for the first time. We have shown that NPY, at
physiological and pathophysiological levels, can induce potent proliferation mediated through
Y5R activation of cell lines of variable metastatic potentials and Y5R expression. Furthermore,
we have illustrated that a transient knockdown of Y5R is sufficient to alter the metastasis of the
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4T1 cell line. These findings support the role of NPY and Y5R in driving the development of
breast cancer tumourigenesis and metastasis.
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Chapter 3- Significance, Limitations, and Future Directions
3.1 Significance
Stress should be adequately appreciated as a supporting and mediating factor of carcinogenesis,
metastasis, and recurrence. The perception of psychosocial and qualitative features of stress
hinders the additional pathophysiological implications that it should hold. Studies have
demonstrated a correlation between elevated stress levels and poor prognosis and survival in
patients with breast cancer.1–5 Additionally, women with a family history of breast cancer release
elevated sympathetic neurotransmitters in response to daily stress.6 Therefore, patients
experiencing normal to chronically elevated stress could be affected by the clinical consequences
of NPY.
The American Society of Clinical Oncology recommends therapy for women with metastatic
breast cancer based on their receptor status (ER, PR, and HER2) and additional biomarkers that
demonstrate clinical utility that have the potential to guide drug regimens.7 In this respect, we
believe that Y5R could be a potential biomarker for breast cancer metastatic potential. We found
that expression of Neuropeptide Y5 Receptor (Y5R) is present in all tested breast cancer lines
and coordinates with metastatic potential. Cytoplasmic receptor localization and quantity were
both associated with enhanced metastatic capacity. This finding could hold prognostic utility in
predicting the likelihood of metastasis. The role of Y5R is not restricted to triple negative breast
cancers, which have the poorest diagnosis associated with a high recurrence rate.8 The previous
finding of Y5R in estrogen receptor positive and negative human breast carcinoma cell lines,
demonstrates the potential role of Y5R in both estrogen receptor positive and negative models.9
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We found that physiologically relevant levels of NPY have the potential to stimulate significant
proliferation of breast cancer lines of variable levels of aggression and Y5R expression. If this
finding is clinically translated to humans, this would provide the impetus to monitor individuals
with a history of breast cancer or post trauma for recurrence or advancement of metastasis.
Further research is required to elaborate on our studies to evaluate the potential of NPY as a
sufficient trigger to induce recurrence by switching growth arrest of dormant breast cancer cells
to form clinically relevant tumours.
One of the most significant findings was the alteration of the metastatic cascade via knockdown
of Y5R in the 4T1 cell line. The five-year survival rate of regional lymph node breast cancer
metastasis of 85.2% drops to 26.3% with distant breast cancer metastasis.10 Breast cancer cells
that metastasize haematogenously readily gain access to capillary beds in common distant sites
of metastasis; lungs, liver, bone and brain. Alternatively, breast cancer cells that metastasize via
the lymph nodes need to enter the blood circulation in order to gain access to these common
distant sites of metastasis.11 Y5R antagonism could have the potential to induce a similar
alteration in the metastatic cascade.
Two Y5R antagonists are safe to administer to patients, MK-0557 (Merck & Co., Inc.) and S2367 (velneperit, Shionogi & Co, Ltd). Both antagonists progressed to phase II trials for obesity,
but were withdrawn given their lack of clinically meaningful effects, though each had some
effect on weight loss.12 Therefore, if the therapeutic potential of Y5R antagonism is clinically
meaningful for breast cancer tumourigenesis and metastasis in humans, the drug safety has
already been validated.
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3.2 Limitations
3.2.1 In vitro MTS proliferation assay
The MTS proliferation assay is a colourimetric quantification of cell viability based on the
reduction of MTS tetrazolium compound to a coloured foramazan product.13 The absorbance is
read and plotted as a gauge of mitochondrial activity and cell viability. A previous study found
that the MTS assay demonstrated a two-fold underestimation of the anti- proliferative effects of
polyphenols, in comparison to the direct measures of ATP and DNA methods.14 Direct measures
that evaluate ATP or DNA could mitigate the limitations of this assay. Furthermore, evaluations
of doubling would provide a quantitative and translatable measure to evaluate proliferation.
Therefore, the ability of stable Y5R antagonism to mitigate cancer cell proliferation could be
enhanced in vivo, compared to our in vitro results. The physiological level of proliferation
induced by NPY and inhibition via Y5R antagonism requires further investigation.

3.2.2 Transient Knockdown of Y5R in the 4T1 Cell Line
shRNA knockdown is achieved through successful vector transfection, transcription of shRNA,
and subsequent sequestration and degradation of the target mRNA.15 Vector transfection permits
exploitation of the cellular transcription machinery to transcribe the shRNA. shRNA integrates
into the endogenous miRNA pathway and induces targeting and degradation by the RNAinduced silencing complex (RISC).16 Although shRNA has had success in suppressing target
expression to inhibit carcinogenesis and metastasis in preclinical models in other studies17–19, we
established a transient knock down of the Y5R in the 4T1 cell line.
We established a 4T1 Y5R-KD with 98.7% GFP+ expression, confirming high vector
transfection. We demonstrated 51% knockdown of the receptor with Western Blotting, which
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was supported by immunocytochemistry of the cell line after one passage. The transient
knockdown was demonstrated by immunohistochemistry of 4T1 Y5R-KD tumours, which
depicted receptor recovery at Day 21 and 28. Therefore, the true contribution of Y5R and the
ability of the receptor’s blockade in mitigating cancerous properties was not fully studied.

3.2.3 Quantification of signal loss in MR images
The presence of iron oxide nanoparticles in a magnetic field causes signal dephasing, altering the
Larmor frequency of surrounding protons and leading to signal loss.20 Quantification of signal
loss in MR images is difficult because (a) the extent of signal loss produced by iron-labeled cells
is not linearly related to the iron concentration and (b) the extent of signal loss produced by ironlabeled cells is much larger than the actual area occupied by the cells; this is known as the
blooming artefact. For example, Heyn et al. found a single signal void measured on average six
voxels, 294µm, and spanned on average three MR slices, 300µm, both dimensions substantially
larger than the size of the cell ~15µm.21 Since cell number cannot be measured from images of
signal loss many studies use measurements of the size of the region of signal loss or the degree
of contrast produced by the iron-labeled cells. In this thesis we measured the signal void volume
within the tumours.
Fluorine-19 (19F) MRI is an alternative approach for cell tracking that circumvents many of the
limitations associated with iron-labeled cell tracking. In comparison to the indirect visualization
of iron oxide nanoparticles by observed image hypointensity, the spins of 19F nuclei are detected
directly and image contrast is proportional to the number of 19F atoms per voxel. This property
mitigates the quantitative concerns with blooming artefacts produced by iron oxide
nanoparticles. Endogenous fluorine does not contribute to measurable tissue background signal,
which prevents non-specific contrast agent identification, allowing for direct quantification of
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labeled cell number. However, compared to iron-labeled cell tracking, sensitivity is low and an
additional proton MR scan is required to attain anatomical context for the 19F signal.

3.2.4 Challenges validating signal loss in MRI using PPB staining
Perls’ Prussian Blue (PPB) was used to stain iron oxide nanoparticles in resected lung and
tumour slices. Signal loss, as a result of iron oxide nanoparticles, in tissues can be readily
identified in MR images due to the blooming artefact. In contrast, PPB staining is a direct
representation of the iron oxide volume present in a slice. Therefore, small quantities of iron are
difficult to detect with histology. In general, it is challenging to compare 10 micron tissue
section with 200 micron image slices. Previous work in the Foster lab has shown that summing
the PPB staining from numerous single tissue sections from a primary tumour will give a better
picture of the quantity and distribution of PPB-positive cells.22 Due to our limited tissue
sampling, we did not overlay stained slices, which hindered our ability to localize iron oxide
nanoparticles with histology in our study.

3.3 Future Directions
In Canada, breast cancer is the most frequently diagnosed cancer in females, with 1 in 9 females
expected to develop breast cancer in their lifetime.23 Metastasis of breast cancer is the culprit of
dropping the 98.8% 5- year survival rate to 26.3%, supporting the need to further explore
biomarkers indicative of cancer cell fate.10 This thesis has explored the implications of the
Neuropeptide Y-Y5R system in breast cancer tumourigenicity and metastasis, providing the
impetus for further investigation of the role of Y5R cellular localization, influence of NPY and
Y5R in vitro and in vivo, the NPY- mediated effects of chronic stress in cancer, and translation to
humans.
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3.3.1 Localization of Y5R
The prevalent nuclear localization of Y5R in the 67NR and 168FARN cell strains and
cytoplasmic localization of Y5R in the 4T1 cell strain is a feature of great interest and should be
further investigated. The effect of NPY at physiological and pathophysiological levels on
receptor localization should be examined. Plasma levels of NPY have been measured in both
stressed and non-stressed conditions, given that NPY has found highly expressed in tumours, it
would be of great interest to evaluate the NPY levels in a tumour of a stressed subject and
induced receptor localization at these concentrations.24
Additionally, further research should examine means of inducing Y5R externalization of the
67NR and 168FARN cell strains via the establishment and characterization of a Y5R knock-in of
the 67NR and 168FARN cell strains. It would be of great significance to contrast the chemoresistant properties of the cell strains in order to elucidate the benefits of basal nuclear
localization of Y5R in the 67NR and 168FARN cell strains.

3.3.2 Influence of NPY in vitro
In order to support NPY- induced carcinogenesis of the 67NR, 168FARN, and 4T1 cell strains,
the influence of NPY on migration and angiogenesis could also be assessed, using assays such as
the modified Boyden chamber and endothelial tube assay, respectively.25,26 These assays have
been previously and effectively used in the Jackson lab to characterize the 4T1 cell strain under
the influence of NPY. Additionally, the role of DPPIV, in cleaving NPY to an abbreviated
Y2/Y5 target, should also be done in order to simulate conditions of the tumour milieu.
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3.3.3 Blockade of Y5R in vivo
The transient reduction of Y5R with shRNA should be further expanded upon to evaluate the
comprehensive contribution of the NPY-Y5R system in driving metastasis. Dr. Phil Medeiros of
the Jackson lab previously administered oral gavage for 50 days of TAC557, a specific Y5R
antagonist, resulting in attenuated tumour burden and lung metastasis.27 This method ensures
longitudinal blockade of the Y5R and would complement longitudinal monitoring of tumour and
metastases development with cellular MRI. Alternatively, genetic knockout of the Y5R in the
4T1 cell strain using the CRISPR/cas9 system could be an avenue of further investigation. In a
comparison of shRNA and CRISPR libraries targeting 93 essential and non-essential genes,
CRISPR outperformed shRNA due to the presence of more functional constructs, apparent
absence of off-target effects, better consistency across cell lines and most importantly sustained
targeting of genes.28

3.3.4 Chronic stress and mice
Upon establishment of sustained Y5R blockade in 4T1 cells and/or up-regulation of Y5R in
67NR or 168FARN cells, the influence of chronic stress resulting in up-regulation of NPY in a
murine model should be investigated. Baldock et al. induced chronic stress resulting in an NPY
plasma levels through a weekly rotation of cold stress, restraint stress, and handling stress for six
weeks that could be administered.29 Due to the extensive tumourigencity and metastasis of the
4T1 cell line after four weeks that we observed, cell implantation should be done at an optimized
time where the mouse has been chronically stressed.

3.3.5 Human tissue studies
This study has demonstrated the variable expression of Y5R of syngeneic murine strains
coordinating with metastatic capacity. Evaluation of NPY and Y5R in human tumours and
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metastases should be investigated. Metastases, recurrence, and survival should also be taken into
account and analyzed. The implications of these studies would demonstrate the utility of Y5R
status as a diagnostic marker and Y5R antagonism as a therapy.
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Appendices

Appendix A. MTS Assay of 67NR, 168FARN and 4T1 Cell Lines with NPY stimulation (1011
M-10-6M) without normalization to basal growth. (A. 67NR) A proliferative effect was
stimulated by NPY at 10-10M, 10-9, 10-7M. (B. 168 FARN) A proliferative effect was stimulated
by NPY at 10-10M, 10-9, 10-7M. (C. 4T1) A proliferative effect was stimulated by NPY at 10-11M,
10-10M, 10-9, 10-7M, 10-6M. (All values were statistically compared to respective control cell
growth, * denotes p<0.05, ** denotes p<0.01, *** denotes p<0.001, One- way ANOVA).
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Appendix B. Control Y5R IHC of BALB/c brain. (A. Positive Control) High fluorescence in
cerebellum showing high Y5R expression (Scale bars=200µm) (A. Positive Control) High
punctate fluorescence showing high Y5R expression (Scale bars=50µm) (C. Negative Control)
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